 EXHIBIT 10.4    \t \t 



Exhibit 10.4

EXECUTION VERSION



SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL
TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN
SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS
HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***] 

--- 
| 

DATED

|

30 May 2018 

 



DENALI THERAPEUTICS INC. (1)

THE SELLERS (2)

and

SHAREHOLDER REPRESENTATIVE SERVICES LLC (as the Sellers' Representative) (3)



__________________________________________________________________________

SHARE PURCHASE AGREEMENT

relating to the entire issued share capital of

F-STAR GAMMA LIMITED

___________________________________________________________________________















![cooleylogo.jpg](cooleylogo.jpg)



COOLEY (UK) LLP, DASHWOOD, 69 OLD BROAD STREET, LONDON EC2M 1QS, UK 
T: +44 (0) 20 7583 4055 F: +44 (0) 20 7785 9355 WWW.COOLEY.COM 

--- 
| | 

CONFIDENTIAL


CONTENTS 

--- 
| | | | 

1.

|

INTERPRETATION

|

|

5

|


 

2.

|

SALE AND PURCHASE

|

|

16

|


 

3.

|

CONSIDERATION

|

|

17

|


 

4.

|

POST COMPLETION ADJUSTMENTS

|

|

19

|


 

5.

|

COMPLETION

|

|

20

|


 

6.

|

ESCROW ACCOUNT

|

|

21

|


 

7.

|

SELLER WARRANTIES AND INDEMNITY

|

|

23

|


 

8.

|

LIMITATIONS TO THE SELLERS' LIABILITY

|

|

24

|


 

9.

|

BUYER'S WARRANTIES

|

|

24

|


 

10.

|

POST COMPLETION MATTERS

|

|

25

|


 

11.

|

BUYER GUARANTEE

|

|

26

|


 

12.

|

SELLERS' REPRESENTATIVE

|

|

28

|


 

13.

|

PAYMENTS

|

|

32

|


 

14.

|

ANNOUNCEMENTS

|

|

32

|


 

15.

|

CONFIDENTIALITY

|

|

33

|


 

16.

|

COSTS

|

|

34

|


 

17.

|

GENERAL

|

|

34

|


 

18.

|

ENTIRE AGREEMENT

|

|

35

|


 

19.

|

ASSIGNMENT

|

|

35

|


 

20.

|

NOTICES

|

|

36

|


 

21.

|

COUNTERPARTS

|

|

37

|


 

22.

|

GOVERNING LAW

|

|

37

|


 

23.

|

DISPUTE RESOLUTION

|

|

37

|


 

24.

|

PROCESS AGENTS

|

|

38

|


 

25.

|

CONFLICT WAIVER

|

|

39

|


 

 




 

--- 
| | 

CONFIDENTIAL

|

2


Agreed Form Documents

| 
---|--- 

1.

|

Disclosure Letter 

| 
---|--- 

2.

|

Escrow Agreement 

| 
---|--- 

3.

|

Loan Notes Instrument 

| 
---|--- 

4.

|

Press Release 

 

 
--- 
| | 

CONFIDENTIAL

|

3




THIS SHARE PURCHASE AGREEMENT is executed and delivered as a DEED on 30 May
2018



BETWEEN:



(1) THE PERSONS, whose names and addresses are set out in Schedule 1 (the
"Sellers");

(2) DENALI THERAPEUTICS INC., a corporation organised and existing under the
laws of the State of Delaware, United States, having its principal place of
business at 201 Gateway Boulevard, South San Francisco, California, United
States (the "Buyer"); and

(3) SHAREHOLDER REPRESENTATIVE SERVICES LLC, a Colorado limited liability
company and which is a party to this Agreement solely in its capacity as
representative of the Sellers (the "Sellers' Representative").

WHEREAS:

| 
---|--- 

(A)

|

The Company is a private limited liability company incorporated under the laws
of England and Wales and engaged in the delivery of therapeutics across the
blood brain barrier. 

| 
---|--- 

(B)

|

As at the date of this Agreement, the Sellers own the Shares that constitute
the entire issued share capital of the Company. The Sellers have agreed to
sell to the Buyer, and the Buyer has agreed to purchase and accept, the Shares
on the terms of this Agreement. 

IT IS AGREED as follows:


 

--- 
| | 

CONFIDENTIAL

|

4


| 
---|--- 

1.

|

INTERPRETATION 

| 
---|--- 

1.1.

|

Definitions 

In this Agreement: 

--- 
| 

"Accepted Fcab Target"

|

is defined in Schedule 5 (Contingent Consideration); 

"Accounting Policies"

|

means the accounting policies and procedures set out in Part C of Schedule 4
(Accounting Policies); 

"Accounts"

|

means the Company's individual accounts (as that term is used in sections 394
and 395 of the Companies Act) and cash flow statement for the financial year
ended on the Last Accounting Date, the auditors' report on those accounts, the
directors' report for that year and the notes to those accounts; 

"Actual Net Cash"

|

has the meaning given to it in Schedule 4. 

"ADR"

|

has the meaning given to it in clause 23.2; 

"Affiliate"

|

means, with respect to a party, any Person that, directly or indirectly,
through one (1) or more intermediaries, controls, is controlled by or is under
common control with such Party. For purposes of this definition, "control"
and, with correlative meanings, the terms "controlling", "controlled by" and
"under common control with" means (a) the possession, directly or indirectly,
of the power to direct the management or policies of a Person, whether through
the ownership of voting securities, by contract relating to voting rights or
corporate governance, or otherwise; or (b) the ownership, directly or
indirectly, of more than fifty percent (50%) of the voting securities or other
ownership interest of a Person (or, with respect to a limited partnership or
other similar entity, its general partner or controlling entity). The parties
acknowledge that in the case of certain entities organized under the laws of
certain countries outside of the United States, the maximum percentage
ownership permitted by law for a foreign investor may be less than fifty
percent (50%), and that in such case such lower percentage shall be
substituted in the preceding sentence, provided that such foreign investor has
the power to direct the management or policies of such entity. "Affiliates"
shall be construed accordingly; 

"Business Day"

|

means a day (other than a Saturday or Sunday) on which banks generally are
open for business in London, UK; 

"Business Warranty"

|

means [***]; 

"Business Warranty Claim"

|

means a claim by the Buyer for breach of a Business Warranty; 

 

 
--- 
| | 

CONFIDENTIAL

|

5

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

"Buyer's Account"

|

means the bank account notified by the Buyer to the Sellers' Representative
from time to time; 

"Buyer's Group"

|

means the Buyer and the Buyer's Group Undertakings; 

"Buyer's Group Undertaking"

|

means the Buyer or an undertaking which is a subsidiary undertaking or parent
undertaking of the Buyer or a subsidiary undertaking of a parent undertaking
of the Buyer and, for the avoidance of doubt, includes the Company from
Completion, and "Buyer's Group Undertakings" shall be construed accordingly; 

"Cash"

|

means the aggregate of all cash held by the Company immediately following
Completion, but excluding the Pass Through Amount; 

"Cash Sellers"

|

means each of the Sellers other than the Loan Note Sellers; 

"Claim"

|

means any Business Warranty Claim, Tax Warranty Claim, Special Indemnity Claim
(including any Fraud Claim), Warrantor Fundamental Warranty Claim and/or
Fundamental Warranty Claim, and "Claims" means any two or more of them; 

"Company"

|

means F-star Gamma Limited, a private limited company incorporated under the
laws of England and Wales under company number 10214672, having its registered
office at Eddeva B920, Babraham Research Campus, Cambridge CB22 3AT; 

"Company Confidential Information"

|

means any Information or data relating to any Fcab or mAb2 Product, any
Exploitation of any Fcab or mAb2 Product, any Know-How with respect thereto
developed by or on behalf of Company or its Affiliates, or the scientific,
regulatory or business affairs or other activities of the Company; 

"Completion"

|

means completion of the sale and transfer of the Shares to the Buyer in
accordance with the terms of this Agreement; 

"Completion Accounts"

|

means the Draft Completion Accounts which have been agreed or determined in
accordance with Part A of Schedule 4 (Preparation of Completion Accounts); 

"Completion Date"

|

means the date on which Completion occurs; 

"Contingent Consideration"

|

has the meaning given to it in paragraph 1 of Part A of Schedule 5 (Contingent
Consideration); 

"Contingent Consideration Loan Notes"

|

means the loan notes which may become issuable by the Buyer to certain of the
Sellers following Completion pursuant to clause 3.5 and/or paragraph 2.3 of
Schedule 5 (Contingent Consideration), to be constituted by the Loan Notes
Instrument; 

"control"

|

has the meaning given to it in section 1124 of the Corporation Tax Act 2010
and "controlling" shall be construed accordingly; 

 

 
--- 
| | 

CONFIDENTIAL

|

6

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

"Declared Distributions"

|

means all dividends and other distributions resolved or declared to be paid or
made, by the Company in respect of the Shares by reference to a record date
which falls on or before Completion; 

"Defaulting Party"

|

has the meaning given to it in clause 5.4; 

[***]

|

has the meaning given to it in the definition of "Initial Amount"; 

"Denali Fcab Notice"

|

has the meaning given to it in the License Agreement; 

[***]

|

has the meaning given to it in the definition of "Initial Amount"; 

"Determination Date"

|

means the date on which the Completion Accounts are agreed or determined in
accordance with the provisions of Part A of Schedule 4 (Preparation of
Completion Accounts); 

"Develop" or "Development"

|

has the meaning given to it in the License Agreement; 

"Disclosure Documents"

|

means the documents attached to the Disclosure Letter; 

"Disclosure Letter"

|

means the letter from the Warrantors to the Buyer in relation to the
Warranties and including the Disclosure Documents having the same date as this
Agreement, the receipt of which has been acknowledged by the Buyer; 

"Dispute"

|

has the meaning given to it in clause 23.1; 

"Disputed Business Warranty Claim"

|

means any Business Warranty Claim that is not yet a Settled Business Warranty
Claim, and "Disputed Business Warranty Claims" shall be construed accordingly; 

"Draft Completion Accounts"

|

means a statement of assets and liabilities for the Company as at the
Effective Time, in the form and with the line items set out in Part B of
Schedule 4 (Completion Accounts) and which has been prepared in accordance
with Part A of Schedule 4 (Preparation of Completion Accounts); 

"Effective Time"

|

means 5 p.m. (London time) on the Completion Date; 

"Encumbrance"

|

means a mortgage, charge, pledge, lien, option, restriction, right of first
refusal, right of pre-emption, third-party right or interest, other
encumbrance or security interest of any kind, or another type of preferential
arrangement (including a title transfer or retention arrangement) having
similar effect, including any such right or interest arising at Completion or
otherwise in connection with this Agreement, and "Encumbrances" shall be
construed accordingly; 

"Escrow Account"

|

means the separately designated interest bearing US dollar deposit account
with SunTrust Bank opened by the Escrow Agent and operated in accordance with
the Escrow Agreement into which payment of the Escrow Amount will be made by
the Buyer at Completion; 

 

 
--- 
| | 

CONFIDENTIAL

|

7

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

"Escrow Agent"

|

means SunTrust Bank to be appointed pursuant to the Escrow Agreement; 

"Escrow Agreement"

|

means the agreement in the agreed form between the Buyer, the Sellers'
Representative and the Escrow Agent in relation to the Escrow Account; 

"Escrow Amount"

|

means [***]; 

"Estimated Net Cash"

|

means such amount in US dollars as is notified in writing by the Sellers to
the Buyer no later than 10 Business Days prior to the Completion Date that is
the good faith estimate by the Sellers of the Net Cash as at the Effective
Time; 

"Exercise Notice"

|

has the meaning given to it in the Option Agreement; 

"Exploitation"

|

has the meaning given to it in the License Agreement; 

"F-star"

|

means F-star Biotechnology Limited, a private limited company incorporated
under the laws of England and Wales under company number 08067987, having its
registered office at Eddeva B920, Babraham Research Campus, Cambridge CB22
3AT; 

"F-star GmbH"

|

means F-star Biotechnologische Forschungs-und entwicklungsges.m.b.h, a limited
liability company incorporated under the laws of the Republic of Austria; 

"Fairly Disclosed"

|

has the meaning given to it in clause 7.5; 

"Fcab Delivery"

|

is defined in Schedule 5 (Contingent Consideration); 

"Fraud Claim"

|

means a claim in respect of fraud, wilful misconduct or wilful concealment by
any of Warrantors (individually or on behalf of the Company) prior to
Completion; 

"Fundamental Warranty"

|

Means [***] and "Fundamental Warranties" means [***]; 

"Fundamental Warranty Claim"

|

means a claim by the Buyer for breach of a Fundamental Warranty; 

"Gamma IP License"

|

means that certain license agreement between the Company and F-star dated 24
August 2016; 

"Gamma Service Agreement"

|

means that certain services agreement between the Company and F-star dated 24
August 2016; 

"Guaranteed Obligations"

|

means all present and future payment obligations and liabilities of the
Company due, owing or incurred under clause 7.5.2 of the Gamma IP License to
F-star (including, without limitation, under any amendment, supplement or
restatement of the Gamma IP License; provided such amendment, supplement or
restatement shall not increase the obligations of the Buyer without the
express consent of the Buyer); 

"HMRC"

|

means HM Revenue and Customs; 

 

 
--- 
| | 

CONFIDENTIAL

|

8

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

"Indebtedness"

|

means the aggregate amount (expressed as a positive number) immediately
following Completion of the following:

a) the principal and accrued interest on any outstanding borrowing or
indebtedness in the nature of borrowing incurred by the Company including,
without limitation, bank debt, loans, overdrafts, guarantees of indebtedness,
letters of credit (which are secured by a third party), any loan notes or
bonds, any other interest bearing and/or secured lending or credit liabilities
provided by third parties to the Company and any early repayment, prepayment,
or break costs, fees or penalties in respect of any such items and any legal
costs and expenses in connection with the release of security in relation to
any such borrowings;

b) all deferred indebtedness of the Company for the payment of the purchase
price of property or assets purchased or services rendered (other than up to
[***] of trade payables and other current liabilities incurred in the ordinary
course of business);

c) all obligations of the Company to pay rent or other payment amounts under
any lease up to and including the Completion Date;

d) reimbursement obligations of the Company with respect to letters of credit,
bankers' acceptances or similar facilities issued for the account of the
Company and that are outstanding as at the Completion Date;

e) all obligations under any interest rate swap agreement, forward rate
agreement, interest rate cap or collar agreement or other financial agreement
or arrangement to which the Company is a party and which was entered into for
the purpose of limiting or managing interest rate risks,

f) all obligations secured by any Encumbrance existing on property owned by
the Company;


 

 

 
--- 
| | 

CONFIDENTIAL

|

9

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

|

g) all premiums, penalties, fees, expenses, breakage costs and change of
control payments required to be paid or offered in respect of any of the
foregoing clauses (b) through (e) as a result of the consummation of the
transactions contemplated by this Agreement or in connection with any lender
consent;

h) all guaranties, endorsements, assumptions and other contingent obligations
of the Company in respect of, or to purchase or to otherwise acquire, any of
the obligations and other matters of the kind described in any of the clauses
(a) through (g) appertaining to third parties; and

i) all liabilities for Taxes incurred by the Company up to, but not paid by,
Completion; 

"Information"

|

means all knowledge of a technical, scientific, business and other nature,
including know-how, technology, means, methods, processes, practices,
formulae, instructions, skills, techniques, procedures, experiences, ideas,
technical assistance, designs, drawings, assembly procedures, computer
programs, apparatuses, specifications, data, results and other material,
regulatory data, and other biological, chemical, pharmacological,
toxicological, pharmaceutical, physical and analytical, pre-clinical,
clinical, safety, manufacturing and quality control data and information,
including study designs and protocols, reagents (e.g., plasmids, proteins,
cell lines, assays and compounds) and biological methodology; in each case
(whether or not confidential, proprietary, patented or patentable, of
commercial advantage or not) in written, electronic or any other form now
known or hereafter developed; 

"Initial Amount"

|

means, where the Buyer serves an Exercise Notice on the Sellers'
Representative and the Company in accordance with the Option Agreement:

a) on a date prior to both [***];

b) on a date that is [***];

c) on a date that is [***]; or

d) after the time period in paragraph (c) above of this definition, [***]; 

 

 
--- 
| | 

CONFIDENTIAL

|

10

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

"Intellectual Property

|

means all intellectual property rights, whether registered or not, including
pending applications for registration of such rights and the right to apply
for registration or extension of such rights including patents, petty patents,
utility models, design patents, designs, copyright (including moral rights and
neighbouring rights), database rights, rights in integrated circuits and other
sui generis rights, trade marks, trading names, company names, service marks,
logos, the get-up of products and packaging and other signs used in trade,
internet domain names, Know How and any rights of the same or similar effect
or nature as any of the foregoing anywhere in the world; 

"Know How"

|

means any and all data, inventions, methods, proprietary information,
processes, trade secrets, techniques and technology, whether patentable or not
but which are not generally known, including discoveries, formulae, materials
(including chemicals), biological materials (including expression constructs,
nucleic acid sequences, amino acid sequences, and cell lines), practices, test
data (including pharmacological, toxicological, pre-clinical and clinical
information and test data), analytical and quality control data (including
drug stability data), manufacturing technology and data (including formulation
data), and sales forecasts, data and descriptions; 

"Last Accounting Date"

|

means 31 December of the financial year on which the Company's last audited
financial statements and accounts were last required to be filed with the UK
Registrar of Companies; 

"License Agreement"

|

means that certain license and collaboration agreement among the Buyer, the
Company, F-star GmbH and F-star, dated 24 August 2016; 

"Loan Note Escrow Account"

|

means the separately designated interest bearing US dollar deposit account
with SunTrust Bank opened by the Escrow Agent and operated in accordance with
the Escrow Agreement into which payment of such amounts as required by clause
3.6 will be made by the Buyer; 

"Loan Note Sellers"

|

each of the Sellers in Schedule 1 marked with an asterisk (*); 

"Loan Notes Instrument"

|

means the loan notes instrument to be issued by the Buyer in the agreed form; 

"Management Accounts"

|

means the unaudited monthly management accounts of the Company in respect of
the period starting on the day after the Last Accounting Date and ending on
the last day of the calendar month preceding the date of this Agreement for
which such accounts have been prepared; 

"Material Contract"

|

has the meaning given to it in clause 7.1.1 of Schedule 7; 

 

 
--- 
| | 

CONFIDENTIAL

|

11

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

"Maximum Contingent Consideration"

|

means:

a) in the event of a [***], provided that if an Initial Payment True Up Event
subsequently occurs, then the Maximum Contingent Consideration will be [***];

b) in the event of a [***], provided that if an Initial Payment True Up Event
subsequently occurs, then the Maximum Contingent Consideration will be [***];

c) in the event of a [***]; or

d) in the event of a [***]; 

"Net Cash"

|

means an amount (which may be a positive or a negative number) equal to the
Cash less the Indebtedness, less Transaction Costs and less Declared
Distributions; 

"Non-defaulting Party"

|

has the meaning given to it in clause 5.4; 

"Notice"

|

has the meaning given to it in clause 20.1; 

"Option Agreement"

|

means that certain option agreement related to the entire issued share capital
of the Company among Buyer, the Company, the Sellers, and the Sellers'
Representative, dated 24 August 2016; 

"Pass Through Amount"

|

means amounts payable by the Company to F-star pursuant to (i) clause 7.5.2 of
the Gamma IP License that have been received by the Company from the Buyer
pursuant to the License Agreement but not paid to F-star as of the Completion
Date; 

"Payments Administrator"

|

means Acquiom Clearinghouse LLC, a Delaware limited liability company; 

"Payment Date"

|

has the meaning given to it in paragraph 1 of Part A of Schedule 5 (Contingent
Consideration); 

"Person"

|

means an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company,
business trust, joint stock company, trust, unincorporated association, joint
venture or other similar entity or organization, including a government or
political subdivision, department or agency of a government; 

[***]

|

has the meaning given to it in the definition of "Initial Amount"; 

[***]

|

has the meaning given to it in the definition of "Initial Amount"; 

"Preliminary Determination Proceeding"

|

has the meaning given to it in paragraph 11.2 of Schedule 8 (Limitations on
Sellers' Liability); 

"Press Release"

|

means a press release regarding Completion in a form agreed between the Buyer
and the Sellers; 

"Proportion of Initial Consideration"

|

has the meaning given to it in clause 3.9;


 

"Release Date"

|

means the date which is [***] from Completion; 

 

 
--- 
| | 

CONFIDENTIAL

|

12

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

"Relevant Shares"

|

means, in relation to each Seller, the number and class of Shares held as at
Completion set out adjacent to that Seller's name in columns B and C of
Schedule 1 (The Sellers); 

"Relief"

|

means any loss, relief, exemption, allowance, deduction, credit or set-off in
respect of Tax or relevant to the computation of Tax and any right to
repayment of Tax; 

"Sellers' Majority"

|

means such of the Sellers who, immediately prior to Completion, together held
not less than a majority in number of the Shares (as determined by reference
to the Shares set out adjacent to each relevant Seller's name in column B of
Schedule 1 (The Sellers)); 

"Set Off Claim"

|

has the meaning given to it in paragraph 11.2 of Schedule 8 (Limitations on
Sellers' Liability); 

"Set Off Dispute Notice"

|

has the meaning given to it in paragraph 11.2 of Schedule 8 (Limitations on
Sellers' Liability); 

"Set Off Notice"

|

has the meaning given to it in paragraph 11.2 of Schedule 8 (Limitations on
Sellers' Liability); 

"Settled Business Warranty Claim"

|

means a Business Warranty Claim or part of a Business Warranty Claim the
quantum of which is:

a) agreed in writing between the Buyer and the Sellers' Representative;

b) determined by [***] court of competent jurisdiction; or

c) determined pursuant to the procedures set forth in clause 23.3; 

"Settled Claim"

|

means a Settled Business Warranty Claim, or a Special Indemnity Claim,
Fundamental Warranty Claim, or Warrantor Fundamental Warranty Claim (or part
thereof), the quantum of which is:

a) agreed in writing between the Buyer and the Sellers' Representative;

b) determined by [***] court of competent jurisdiction; or

c) determined pursuant to the procedures set forth in clause 23.3; 

"Shareholders' Agreement"

|

means the shareholders' agreement between the Shareholders and the Company
dated 24 August 2016; 

"Shareholder Arrangements"

|

means any advisory, contractual or commercial arrangements relating to the
Company (including the existing shareholders agreement relating to the
Company) to which any or all of the Sellers and/or any of their Affiliates are
a party (excluding any employment agreement or consultancy agreement between
those Sellers who are employees or consultants and the Company); 

"Shares"

|

means all of the issued ordinary shares in the capital of the Company from
time to time; 

 

 
--- 
| | 

CONFIDENTIAL

|

13

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

"Shortfall"

|

has the meaning given to it in clause 5.1(a); 

[***]

|

has the meaning given to it in clause 6.3; 

"Special Indemnity Claim"

|

means a claim in respect of any of the Special Indemnity Matters and "Special
Indemnity Claims" shall be construed accordingly; 

"Special Indemnity Matter"

|

means [***] and "Special Indemnity Matters" means [***]; 

"Tax", "Taxes" or "Taxation"

|

means all forms of taxation, duties and withholdings in respect of taxation
imposed in the United Kingdom or elsewhere (including National Insurance
contributions) and all interest, penalties, charges and fines in respect of
any of them; 

"Tax Authority"

|

means HMRC and any other authority, body or official (whether in the United
Kingdom or elsewhere) competent to assess, demand, impose, administer or
collect Tax or make any decision or ruling on any matter relating to Tax; 

"Tax Warranty"

|

means [***] and "Tax Warranties" means [***]; 

"Tax Warranty Claim"

|

means a claim in respect of any breach of any of the Tax Warranties; 

"Third Party"

|

has the meaning given to it in the License Agreement; 

"Total Consideration"

|

has the meaning given to it in clause 3.1; 

"Total Contingent Consideration"

|

has the meaning given to it in paragraph 1 of Part A of Schedule 5 (Contingent
Consideration); 

"Transaction Costs"

|

means all third party fees, costs, expenses, payments, and expenditures
incurred by the Company in connection with the transactions contemplated by
this Agreement whether or not billed or accrued (including any fees, costs
expenses, payments, and expenditures of legal counsel and accountants, the
maximum amount of fees costs, expenses, payments, and expenditures payable to
financial advisors, investment bankers and brokers of the Company
notwithstanding any contingencies for earnouts, escrows, etc., and any such
fees, costs, expenses, payments, and expenditures incurred by the Sellers paid
for or to be paid for by the Company); 

"Transaction Documents"

|

means this Agreement, the Option Agreement, the License Agreement, the Gamma
IP License, the Loan Note Instrument, the Disclosure Letter, the Escrow
Agreement and the Gamma Service Agreement; 

"Upfront Consideration"

|

has the meaning given to it in clause 3.2;


 

"Warrantor Fundamental Warranties"

|

means [***];


 

"Warrantor Fundamental Warranty Claim"

|

means a claim by the Buyer for breach of a Warrantor Fundamental Warranty; 

 

 
--- 
| | 

CONFIDENTIAL

|

14

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| 

"Warrantors"

|

means [***], save that if any such person ceases to be employed or otherwise
engaged by F-star GmbH (or any of its Affiliates) in a management position or
ceases to own (legally or beneficially) Shares then they shall cease to be a
Warrantor and shall be replaced as a Warrantor by the person then performing
the role of [***], or, in any case, by such person as the Company, acting
reasonably, may nominate in writing provided that such person owns Shares
(legally or beneficially), performs a senior management role in the Company
and the Buyer consents to the appointment, such consent not to be unreasonably
withheld, conditioned or delayed, and a "Warrantor" means any one of them; and 

"Warranty"

|

means [***] and "Warranties" means [***]. 

 

| 
---|--- 

1.2.

|

Clause, Schedule and paragraph headings shall not affect the interpretation of
this Agreement. 

| 
---|--- 

1.3.

|

References to clauses and Schedules are to the clauses and Schedules of this
Agreement and references to paragraphs are to paragraphs of the relevant
Schedule. 

| 
---|--- 

1.4.

|

The Schedules form part of this agreement and shall have effect as if set out
in full in the body of this Agreement. Any reference to this agreement
includes the Schedules. 

| 
---|--- 

1.5.

|

A "subsidiary" or "holding company" is to be construed in accordance with
section 1159 (and Schedule 6) of the Companies Act and a "subsidiary
undertaking" or "parent undertaking" is to be construed in accordance with
section 1162 (and Schedule 7) of the Companies Act; 

| 
---|--- 

1.6.

|

A person includes a natural person, corporate or unincorporated body (whether
or not having separate legal personality). 

| 
---|--- 

1.7.

|

A reference to a party shall include that party's personal representatives,
successors and permitted assigns. 

| 
---|--- 

1.8.

|

Unless the context otherwise requires, words in the singular shall include the
plural and in the plural shall include the singular. 

| 
---|--- 

1.9.

|

Unless the context otherwise requires, a reference to one gender shall include
a reference to the other genders. 

| 
---|--- 

1.10.

|

A reference to writing or written includes fax and e-mail (unless otherwise
expressly provided in this Agreement). 

 

 
--- 
| | 

CONFIDENTIAL

|

15

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

1.11.

|

The ejusdem generis principle of construction shall not apply to this
Agreement. Accordingly, any words following the terms including, include, in
particular, for example or any similar expression shall be construed as
illustrative and shall not limit the sense of the words, description,
definition, phrase or term preceding those terms. Where the context permits,
other and otherwise are illustrative and shall not limit the sense of the
words preceding them. 

| 
---|--- 

1.12.

|

A reference to a document in this Agreement in the agreed form is to a
document agreed by the parties and initialled by them or on their behalf for
identification purposes. 

| 
---|--- 

1.13.

|

Where any obligation in this Agreement is expressed to be undertaken or
assumed by any party, that obligation is to be construed as requiring the
party concerned to exercise all rights and powers of control over the affairs
of any other person which it is able to exercise (whether directly or
indirectly) in order to secure performance of the obligation. 

| 
---|--- 

1.14.

|

References to any English legal term for any action, remedy, method of
judicial proceeding, legal document, legal status, court, official or any
other legal concept shall, in respect of any jurisdiction other than England,
be deemed to include the legal concept which most nearly approximates in that
jurisdiction to the English legal term. 

| 
---|--- 

1.15.

|

A reference to a statute or statutory provision is a reference to it as
amended, extended or re-enacted from time to time. 

| 
---|--- 

1.16.

|

References to "US$" or "$" are references to US dollars, legal tender in the
United States, and references to "GBP" or "Â£" are references to pounds
sterling, legal tender in the United Kingdom. 

| 
---|--- 

2.

|

SALE AND PURCHASE 

| 
---|--- 

2.1.

|

Each Seller severally agrees to sell or procure the sale to the Buyer, and the
Buyer agrees to buy, all of such Seller's Relevant Shares together with all
rights attaching to those Relevant Shares at Completion, free from any
Encumbrance and with full title guarantee. 

| 
---|--- 

2.2.

|

Each Seller severally waives all rights of pre-emption, rights of first
refusal and any other similar rights or other restrictions on transfer
conferred on that Seller by the Company's articles of association or otherwise
over any of the Relevant Shares. 

| 
---|--- 

2.3.

|

The Buyer shall be responsible for the payment of all stamp duty (and, if
applicable, stamp duty reserve tax) on this Agreement and the transfers in
respect of the Shares at Completion. 

| 
---|--- 

2.4.

|

In the event that the Buyer becomes aware that it or the Escrow Agent will
have an obligation to deduct or withhold an amount for or on account of Taxes
from any payment made under this Agreement, it shall notify the Sellers'
Representative in writing as soon as reasonably 

 

 
--- 
| | 

CONFIDENTIAL

|

16

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

practicable and the parties shall use their reasonable endeavours to do, to
the extent within their power and authority, all such acts and things and to
sign all such documents as will enable them to take advantage of any
applicable double taxation agreement, treaty or domestic exemption which may
apply to eliminate or reduce withholding Taxes and otherwise provide the
Sellers such assistance as is reasonably required to obtain a refund of the
withheld or similar Taxes, or obtain a credit with respect to such Taxes. In
the event there is no applicable double taxation agreement, treaty or domestic
exemption or if an applicable double taxation agreement, treaty or domestic
exemption reduces but does not eliminate such withholding or similar Tax, the
Buyer or Escrow Agent shall deduct the amount paid from the amount due to the
respective Seller or Sellers, remit such withholding or similar Tax to the
appropriate Tax Authority and secure and send to the respective Seller or
Sellers reasonable evidence of the payment of such withholding or similar Tax.
In the event that any Taxes are required by applicable Tax law to be withheld
or deducted for or on account of Tax from any payments made under this
Agreement, any Taxes so withheld and deducted from any payment by the Buyer or
the Escrow Agent and paid over to the appropriate Tax Authority shall be
treated as paid to the Sellers under this Agreement.

| 
---|--- 

3.

|

CONSIDERATION 

| 
---|--- 

3.1.

|

The purchase price for the Shares shall be an amount equal to: 

| 
---|--- 

(a)

|

the Upfront Consideration; and 

| 
---|--- 

(b)

|

any Contingent Consideration, 

(collectively, the "Total Consideration").

Upfront Consideration

| 
---|--- 

3.2.

|

The aggregate consideration payable by the Buyer to the Sellers for the Shares
pursuant to this Agreement on the Completion Date shall be: 

| 
---|--- 

(a)

|

the Initial Amount; plus 

| 
---|--- 

(b)

|

the Estimated Net Cash, 

(the amount set out in clause 3.2(a) plus the amount set out in clause 3.2(b)
being the "Initial Consideration"), as increased by the amount to be paid by
the Buyer or, as the case may be, decreased by the amount to be paid by the
Sellers, pursuant to clause 4.1 (the total sum being referred to as the
"Upfront Consideration).

| 
---|--- 

3.3.

|

At Completion, the Buyer shall pay: 

 

 
--- 
| | 

CONFIDENTIAL

|

17

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

(a)

|

an amount in cash equal to the Initial Consideration less the Escrow Amount,
by transfer of funds for same day value to the Payments Administrator in
accordance with clause 13.1; and 

| 
---|--- 

(b)

|

the Escrow Amount into the Escrow Account by transfer of funds for same day
value. 

| 
---|--- 

3.4.

|

The parties agree to comply with their respective obligations under Part A of
Schedule 4 (Preparation of Completion Accounts). 

Contingent Consideration

| 
---|--- 

3.5.

|

If any of the Milestone Events set forth in Schedule 5 (Contingent
Consideration) are achieved, the Buyer will make the corresponding Milestone
Payment to the Payments Administrator for further distribution to the Sellers
on or prior to the Payment Date. Any Contingent Consideration payable to the
Sellers shall be allocated between the Sellers with regard to their respective
Proportion of Initial Consideration or as otherwise notified to the Buyer in
writing by the Sellers' Representative at least five (5) Business Days prior
to a Payment Date and shall be satisfied: 

| 
---|--- 

(a)

|

in respect of the Loan Note Sellers, by the issue by the Buyer of the
Contingent Consideration Loan Notes to each of the Loan Note Sellers equal, in
principal amount, to the relevant Contingent Consideration due to such Loan
Note Sellers; and 

| 
---|--- 

(b)

|

in respect of the Cash Sellers, by paying the relevant Contingent
Consideration due to each of the Cash Sellers to the Payments Administrator in
accordance with clause 13 on a Payment Date. 

| 
---|--- 

3.6.

|

Simultaneously with the issue by the Buyer of any Contingent Consideration
Loan Notes to the Loan Note Sellers in accordance with clause 3.5(a), the
Buyer shall transfer to the Loan Note Escrow Account an amount equal to the
total aggregate principal amount of such Contingent Consideration Loan Notes,
which amount (together with any interest accrued thereon) shall be released by
the Escrow Agent to the Loan Note Sellers within five (5) Business Days
following redemption of such Contingent Consideration Loan Notes in accordance
with the Loan Note Instrument. The Escrow Agent may withdraw from the Loan
Note Escrow Account an amount equal to any Tax on the interest earned in
respect of money held in the Loan Note Escrow Account for which it is liable. 

| 
---|--- 

3.7.

|

The Total Contingent Consideration shall not under any circumstances exceed
the Maximum Contingent Consideration. 

| 
---|--- 

3.8.

|

The Buyer shall (and shall procure that all relevant Buyer's Group
Undertakings shall) comply with the provisions of Schedule 5 (Contingent
Consideration). 

 

 
--- 
| | 

CONFIDENTIAL

|

18

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

3.9.

|

The proportion of the Initial Consideration, to which each Seller is entitled
is set against his name in column D of Schedule 1 (The Sellers) (each, a
"Proportion of Initial Consideration"). 

Consideration Generally

| 
---|--- 

3.10.

|

Each Seller agrees to the allocation of the Total Consideration as provided
for in this Agreement (including any allocation notified to the Buyer by the
Sellers' Representative pursuant to clause 3.5) and waives any claim or
dispute regarding the apportionment of the proceeds from the sale of his
Shares provided it is made in accordance with this Agreement. Following any
payment to the Payments Administrator in accordance with this Agreement, the
Buyer shall be under no obligation to see that any such amounts are divided
and paid to each Seller (or any other person). 

| 
---|--- 

3.11.

|

If, after Completion, any Seller is in or comes into possession of any amounts
attributable to any other Seller then as soon as reasonably practicable
following any request by the Seller which has the right to such amounts, the
relevant Seller shall use all reasonable endeavours to ensure that the person
in possession of that relevant amount does or causes to be done all such
things as the Seller entitled to such amount may from time to time reasonably
require, in order to transfer possession of such relevant amount to the owner. 

| 
---|--- 

4.

|

POST COMPLETION ADJUSTMENTS 

| 
---|--- 

4.1.

|

If the amount of the Actual Net Cash: 

| 
---|--- 

(a)

|

is less than the amount of the Estimated Net Cash, then, subject to clause
5.3, the Sellers shall pay the Buyer an amount equal to the amount of such
shortfall (the "Shortfall"); or 

| 
---|--- 

(b)

|

exceeds the amount of the Estimated Net Cash, the Buyer shall pay the Sellers
an amount equal to the amount of such excess, 

in either case, together with an amount equal to interest on such sum
calculated on a daily basis at a rate of [***] from (and including) the
Completion Date to (but excluding) the date of actual payment, in accordance
with the provisions of clauses 4.2 and 4.3.

| 
---|--- 

4.2.

|

Payments made by the Buyer pursuant to clause 4.1(b) shall be made by transfer
of funds for same day value (to the Payments Administrator in accordance with
clause 13.1), within two (2) Business Days of the Determination Date without
set off, deduction or withholding (except as required by law or by this
Agreement). 

| 
---|--- 

4.3.

|

If an amount is payable by the Sellers pursuant to clause 4.1(a), such amount
shall be paid from the Escrow Account to the Buyer when the Buyer and the
Sellers' Representative within 

 

 
--- 
| | 

CONFIDENTIAL

|

19

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

two (2) Business Days of the Determination Date jointly instruct the Escrow
Agent in writing to make such payment out of amounts standing to the credit of
the Escrow Account to the Buyer's Account in accordance with clause 13.2.

| 
---|--- 

5.

|

COMPLETION 

| 
---|--- 

5.1.

|

Completion shall take place at the offices of the Seller's Solicitors
immediately following the execution of this Agreement. 

| 
---|--- 

5.2.

|

At Completion each Seller and the Buyer shall do all those things respectively
required of each of them in Schedule 3 (Completion Requirements). 

| 
---|--- 

5.3.

|

Neither the Sellers nor the Buyer are obliged to complete this Agreement
unless: 

| 
---|--- 

(a)

|

all of the Sellers (in the case of the Buyer) or the Buyer (in the case of the
Sellers) comply with all its/their obligations under this clause 5 and
Schedule 3 (Completion Requirements); and 

| 
---|--- 

(b)

|

subject to the provisions of clause 7 of the Option Agreement, the purchase of
all the Shares under this Agreement is completed simultaneously. 

| 
---|--- 

5.4.

|

If Completion does not take place immediately following the execution of this
Agreement because the Buyer or any Seller (the "Defaulting Party") fails to
comply with any of its obligations under this clause 5 and Schedule 3
(Completion Requirements) (whether such failure amounts to a repudiatory
breach or not) (a "Material Default"), the Buyer (if the Defaulting Party is a
Seller) or the Company (if the Defaulting Party is the Buyer) (the "Non-
defaulting Party") may by notice to the Defaulting Party: 

| 
---|--- 

(a)

|

proceed to Completion to the extent reasonably practicable (without limiting
its rights under this Agreement); 

| 
---|--- 

(b)

|

postpone Completion to such date as the Non-defaulting Party may specify; or 

| 
---|--- 

(c)

|

terminate this Agreement by notice in writing to the Defaulting Party (a
"Termination Notice") save that the Non-defaulting Party shall have five (5)
Business Days from receipt of the Termination Notice to remedy such Material
Default (provided, however, that no such cure period shall be available or
applicable to any such Material Default which by its nature cannot be cured).
In the event that the Material Default is capable of being remedied but is not
so remedied within the requisite time period, this Agreement shall terminate
upon expiry of the period of five (5) Business Days without further action by
either party. If the Material Default is remedied within the requisite time,
the Termination Notice shall lapse and 

 

 
--- 
| | 

CONFIDENTIAL

|

20

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

Completion shall be deemed to have been postponed until such date as the Non-
defaulting Party may determine.

| 
---|--- 

5.5.

|

If the Non-defaulting Party postpones Completion to another date in accordance
with clause 5.4(b), or if Completion is deemed to have been postponed to
another date in accordance with clause 5.4(c), the provisions of this
Agreement apply as if that other date is the Completion Date. 

| 
---|--- 

5.6.

|

If the Non-defaulting Party terminates this Agreement pursuant to clause
5.4(c), each party's further rights and obligations cease immediately on
termination, but termination does not affect a party's accrued rights and
obligations at the date of termination. 

| 
---|--- 

5.7.

|

The parties agree that except in the case of fraud, wilful misconduct or
wilful concealment on behalf of the Sellers or the Buyer, rescission shall not
be available as a remedy for any breach of this Agreement. 

| 
---|--- 

5.8.

|

Nothing in this clause 5 shall prevent a Non-defaulting Party from exercising
remedies available to it under applicable law. 

| 
---|--- 

6.

|

ESCROW ACCOUNT 

| 
---|--- 

6.1.

|

Each party agrees that the money in the Escrow Account shall only be used in
accordance with the provisions set out in clause 4, this clause 6, paragraph 5
of Part A of Schedule 4 (Preparation of Completion Accounts) and the Escrow
Agreement. 

| 
---|--- 

6.2.

|

Each party shall ensure that all rights to the Escrow Account remain free from
any Encumbrance, set off or counterclaim except as referred to in this clause
6. 

| 
---|--- 

6.3.

|

The liability of any Warrantor in respect of [***] shall be limited by the
amount of money standing to the credit of the Escrow Account from time to time
and the sole remedy of the Buyer under this Agreement in respect of a [***]
shall be the release of any such amount to the Buyer from the Escrow Account. 

| 
---|--- 

6.4.

|

A [***] must be satisfied out of and deducted from the money in the Escrow
Account in accordance with this clause 6 and a Shortfall must be first
satisfied out of and deducted from the money in the Escrow Account in
accordance with this clause 6. In addition, in the event of [***]. 

| 
---|--- 

6.5.

|

To the extent that liability for [***] is to be satisfied from the Escrow
Account, each Warrantor shall be [***] liable to the Buyer for such liability
up to the availability of any amount standing to the credit of the Escrow
Account from time to time irrespective of the amount (if any) contributed to
the Escrow Account by such Warrantor. 

 

 
--- 
| | 

CONFIDENTIAL

|

21

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

6.6.

|

No Warrantor shall have any liability to any other Seller in respect of any
liability satisfied from the Escrow Account. 

| 
---|--- 

6.7.

|

Clauses 6.3 and 6.6 shall not apply so as to limit the liability of any
Warrantor in respect of any fraud by such Warrantor or any remedy available to
any other Seller or the Buyer in respect thereof. 

| 
---|--- 

6.8.

|

Interest accruing from time to time on the balance of money standing to the
credit of the Escrow Account shall be added to the money standing to the
credit of the Escrow Account and shall form part of it for the purposes of
this clause 6. 

| 
---|--- 

6.9.

|

All of the costs (including reasonable legal costs) and expenses (together
with any applicable VAT), in each case, of any nature whatsoever, of the
Escrow Agent in relation to the Escrow Account and the Escrow Agreement shall
be deemed to be Transaction Costs. 

| 
---|--- 

6.10.

|

The Escrow Agent may withdraw from the Escrow Account an amount equal to any
Tax on the interest earned in respect of money held in the Escrow Account for
which it is liable. 

| 
---|--- 

6.11.

|

On the Release Date, the money then standing to the credit of the Escrow
Account less the total of the then outstanding Disputed Business Warranty
Claims and less any amount that has not yet been paid in accordance with
clause 4 or paragraph 5 of Part A of Schedule 4 (Preparation of Completion
Accounts) shall be paid to the Payments Administrator in accordance with
clause 13.1. After that date, to the extent that the money standing to the
credit of the Escrow Account from time to time exceeds the total of the then
outstanding Disputed Business Warranty Claims and any amount that has not yet
been paid in accordance with clause 4 or paragraph 5 of Part A of Schedule 4
(Preparation of Completion Accounts), that money shall be paid to the Payments
Administrator in accordance with clause 13.1. 

| 
---|--- 

6.12.

|

If the Sellers or the Buyer are entitled to money from the Escrow Account
under clauses 6.4 or 6.11, the Sellers' Representative and the Buyer shall
within five (5) Business Days of the date on which the entitlement arises
jointly instruct the Escrow Agent in writing to release the money to the
Payments Administrator in accordance with clause 13.1 or the Buyer, as the
case may be, together with an amount (less any Tax and other amount the Escrow
Agent is legally required to deduct from that amount) equal to the interest
actually accrued on such sum calculated for the period from (and including)
the date of this Agreement to (but excluding) the date of payment. 

| 
---|--- 

6.13.

|

All payments made to the Buyer by the Escrow Agent under this clause 6 shall
be made gross and without deduction or withholding of any kind other than any
deduction or withholding required by law. 

 

 
--- 
| | 

CONFIDENTIAL

|

22

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

6.14.

|

The amount, if any, of the Escrow Amount which is paid to the Buyer pursuant
to clause 4.2 or this clause 6 shall be treated as a reduction in the Total
Consideration. 

| 
---|--- 

6.15.

|

The Sellers agree between themselves that any amounts released to the Payments
Administrator for further distribution to the Sellers from the Escrow Account
shall be apportioned between them by reference to their respective
contribution initially made to the Escrow Amount (as set out in column F of
the table in Schedule 1 (The Sellers). 

| 
---|--- 

7.

|

SELLER WARRANTIES AND INDEMNITY 

| 
---|--- 

7.1.

|

Each Seller (i) [***] warrants [***] to the Buyer in the terms of the
Fundamental Warranties at Completion and, subject to clause 7.4, the Tax
Warranties at Completion; and (ii) subject to the limitations set forth in
Schedule 8 (Limitations on the Sellers' Liability) agrees [***], and on a pro
rata basis in accordance with each Seller's Proportion of Initial
Consideration, to indemnify the Buyer against any losses, costs, claims,
liabilities, damages, demands and expenses arising out of any Special
Indemnity Matter save where such losses, costs, claims, liabilities, damages,
demands and/or expenses are a result of any action or omission by or on behalf
of the Buyer (or any Buyer's Group Undertaking) or due to the Buyer's (or any
Buyer's Group Undertaking's) gross negligence, wilful misconduct or wilful
concealment. 

| 
---|--- 

7.2.

|

Each Warrantor [***] warrants [***] to the Buyer in the terms of the Warrantor
Fundamental Warranties at Completion. 

| 
---|--- 

7.3.

|

Subject to clause 7.4, each Warrantor [***] warrants to the Buyer on the terms
of the Business Warranties at Completion. 

| 
---|--- 

7.4.

|

[***]. For the avoidance of doubt, [***]. 

| 
---|--- 

7.5.

|

[***]. 

| 
---|--- 

7.6.

|

Where [***] is qualified by the expression "so far as the Warrantors are
aware" or "to the best of the knowledge, information and belief of the
Warrantors" or qualified by any similar expression, each Warrantor shall be
deemed only to have knowledge of anything of which [***]. 

| 
---|--- 

7.7.

|

Each Seller agrees and undertakes to the Buyer and to each person referred to
in this clause 7.7 that, except in the case of fraud, it will not make any
claim against the Company or any director, officer or employee of the Company
on whom it may have relied before agreeing any term of this Agreement or any
of the transaction contemplated by this Agreement which it may have in respect
of a misrepresentation, inaccuracy or omission in or from information or
advice provided by any such person for the purpose of assisting any such
Seller to make a representation, give a Warranty or prepare the Disclosure
Letter (as applicable). After 

 

 
--- 
| | 

CONFIDENTIAL

|

23

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

Completion, the Company or any director, officer or employee of the Company
may enforce the terms of this clause 7.7 subject to and in accordance with
[***].

| 
---|--- 

7.8.

|

[***]. 

| 
---|--- 

8.

|

LIMITATIONS TO THE SELLERS' LIABILITY 

| 
---|--- 

8.1.

|

Each Seller's liability for [***] and each Warrantor's liability for [***]
shall be limited or excluded, as the case may be, as set out in clause 7 and
Schedule 8 (Limitations on the Sellers' Liability). 

| 
---|--- 

8.2.

|

Except as stated in this Agreement, the Buyer shall not be restricted from
including as part of any Claim any losses, costs, claims, liabilities,
damages, demands and/or expenses [***]. 

| 
---|--- 

9.

|

BUYER'S WARRANTIES 

The Buyer warrants to each Seller as at Completion that:

| 
---|--- 

9.1.

|

it is a company duly incorporated and validly existing in the State of
Delaware, United States and has the right, power and authority to execute,
deliver and perform its obligations under this Agreement and any other
Transactional Document to be executed by it; 

| 
---|--- 

9.2.

|

the Buyer's obligations under this Agreement and any other Transactional
Documents to be executed by the Buyer are, or when the relevant document is
executed will be, enforceable in accordance with their terms, subject to the
effects of bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other similar laws relating to or affecting creditors' rights
generally and general equitable principles; 

| 
---|--- 

9.3.

|

the execution, delivery and performance by the Buyer of this Agreement and
each Transactional Document to be executed by it will not breach any provision
of the certificate of incorporation or bylaws of the Buyer or breach any
applicable laws or regulations, or any orders, judgements or decrees which the
Buyer is bound by or result in a breach of or constitute a default under any
instrument, contract or agreement to which the Buyer is a party or by which
the Buyer is bound and which, in each case, is material in the context of the
transactions contemplated by this Agreement and any of the Transactional
Documents; and 

| 
---|--- 

9.4.

|

it has available on an unconditional basis (subject only to Completion) the
necessary resources to meet its obligations under this Agreement, other than
payment of the Contingent Consideration. 

 

 
--- 
| | 

CONFIDENTIAL

|

24

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

10.

|

POST COMPLETION MATTERS 

| 
---|--- 

10.1.

|

Each Seller agrees in respect only of itself that the Seller shall, for so
long as the Seller remains the registered holder of any of the Relevant Shares
after Completion, hold those Relevant Shares with all rights and benefits
attaching or accruing to them on or after the date of this Agreement as bare
trustee for the Buyer absolutely. 

| 
---|--- 

10.2.

|

For a period of [***] after Completion each Seller hereby irrevocably
undertakes to the Buyer pending registration by the Company of the transfer of
the Seller's Relevant Shares to the Buyer, to exercise any votes attaching to
any of the Seller's Relevant Shares or sign any consent to short notice of a
general meeting (or written resolution in lieu thereof) as the Buyer may
reasonably direct. 

| 
---|--- 

10.3.

|

Each Seller acting severally shall execute and shall procure the execution of,
all documents and deeds and/or do or procure the doing of, all acts and things
that the Buyer reasonably requires after Completion to vest in the Buyer legal
title to and the full benefit of the Relevant Shares held by such Seller. 

| 
---|--- 

10.4.

|

Subject to clause 10.5, each of the Sellers (for itself and for and on behalf
of each of its Affiliates) hereby irrevocably agrees that, with effect from
and conditional upon Completion: 

| 
---|--- 

(a)

|

the Shareholder Arrangements are hereby terminated; 

| 
---|--- 

(b)

|

any and all rights of any Seller and/or any of its Affiliates and any and all
obligations of the Company under, pursuant to or in connection with the
Shareholder Arrangements, along with any other claim or demand of any Seller
or any of its Affiliates against the Company, which are subsisting or
outstanding at the date of this Agreement are expressly waived and released,
including any and all such rights and obligations, claims and demands which
may have accrued in respect of any period prior to Completion; and 

| 
---|--- 

(c)

|

any and all other debts or liabilities (whether actual, contingent or
prospective and including any interest thereon) of the Company to any Seller
under, pursuant to or in connection with the Shareholder Arrangements or
otherwise which are subsisting or outstanding at the date of this Agreement
are expressly waived, released and discharged. 

| 
---|--- 

10.5.

|

Each Seller shall ensure that at Completion there will be no amounts owing by
the Company to such Seller in respect of itself and its Affiliates only, other
than by way of accrued but unpaid salary or consultancy fees or unreimbursed
expenses incurred in the ordinary course of business consistent with past
practice owed to employees or consultants of the Company. 

 

 
--- 
| | 

CONFIDENTIAL

|

25

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

10.6.

|

The Buyer shall, within 20 Business Days of Completion, procure that the name
of the Company is changed to such name as the Buyer may decide provided that
it does not include the word "F-star". 

| 
---|--- 

10.7.

|

The Buyer intends to make an election under Section 338(g) of the United
States Internal Revenue Code of 1986, as amended (the "IRC") (and any
corresponding election under state and local Tax law) with respect to the
purchase of the Shares under this Agreement (collectively, the "Section 338
Election"). The Buyer may make the Section 338 Election in its sole
discretion; provided, however, that the Sellers shall not be liable in respect
of a Tax Warranty Claim for any liability of the Company for Taxes arising
directly or indirectly from the Section 338 Election and the Buyer shall
indemnify the Sellers and the Company on an after-Tax basis against any Tax
liability, losses and all reasonable costs and expenses of the Sellers or the
Company which arise directly or indirectly as a result of the Section 338
Election being made excluding any Tax liability, losses or costs and expenses
that would have not have arisen had all of the Tax Warranties made by the
Company and Sellers been true, correct and complete. In addition, in the case
of any Seller, the calculation of any increase in Tax liability of such Seller
resulting from the Section 338 Election shall be made assuming (a) that such
Seller and any of its direct or indirect owners has made a timely and valid
election under Section 1295 of the U.S. Internal Revenue Code of 1986, as
amended (the "Code") and the regulations thereunder to treat its shares in the
Company as a "qualified electing fund" within the meaning of Section 1295
effective with the first day of such Seller's holding period in the Company's
shares and (b) that the Company is not, and has not at any time during the
five (5) taxable years preceding the Completion Date, been a "controlled
foreign corporation" within the meaning of Section 957 of the IRC. For
clarify, Purchaser shall not be required under this Section 10.7 to indemnify
the Company or any Seller for any Tax liability that would not have arisen had
a Seller (or its direct or indirect owners) elected to treat the Company as a
qualified electing fund and/or had the Company not been a controlled foreign
corporation, as described in the previous sentence. 

| 
---|--- 

11.

|

BUYER GUARANTEE 

| 
---|--- 

11.1.

|

Following Completion, the Buyer guarantees to F-star, whenever the Company
does not pay any of the Guaranteed Obligations when due, to pay within 5
Business Days following receipt of written demand from F-star, the Guaranteed
Obligations. 

| 
---|--- 

11.2.

|

Following Completion, the Buyer as principal obligor and as a separate and
independent obligation and liability from its obligations and liabilities
under clause 11.1 agrees to indemnify and keep indemnified F-star in full and
on written demand from and against all and any losses, costs, claims,
liabilities, damages, demands and expenses suffered or incurred by F-star
arising directly out of the Guaranteed Obligations not being recoverable for
any 

 

 
--- 
| | 

CONFIDENTIAL

|

26

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

reason or any failure of the Company to pay any of its obligations or
liabilities in respect of the Guaranteed Obligations.

| 
---|--- 

11.3.

|

This guarantee is and shall cover the ultimate balance from time to time owing
to F-star by the Company in respect of the Guaranteed Obligations. 

| 
---|--- 

11.4.

|

The liability of the Buyer under this clause 11 shall not be terminated by: 

| 
---|--- 

(a)

|

any intermediate payment, settlement of account or discharge in part of the
Guaranteed Obligations; 

| 
---|--- 

(b)

|

any variation, extension, discharge, compromise, dealing with, exchange or
renewal of any right or remedy which F-star may now or after the date of this
guarantee have from or against any of the Company and any other person in
connection with the Guaranteed Obligations; 

| 
---|--- 

(c)

|

any amendment, variation, novation, replacement or supplement of or to any of
the Guaranteed Obligations; 

| 
---|--- 

(d)

|

any grant of time, indulgence, waiver or concession to the Company or any
other person; 

| 
---|--- 

(e)

|

any insolvency, bankruptcy, liquidation, administration, winding up,
incapacity, limitation, disability, the discharge by operation of law, or any
change in the constitution, name or style of the Company, F-star, or any other
person; 

| 
---|--- 

(f)

|

any claim or enforcement of payment from the Company or any other person; or 

| 
---|--- 

(g)

|

any act or omission which would not have discharged or affected the liability
of the Buyer had it been a principal debtor instead of a guarantor, or
indemnifier or by anything done or omitted by any person which, but for this
provision, might operate to exonerate or discharge the Buyer or otherwise
reduce or extinguish its liability under this guarantee. 

| 
---|--- 

11.5.

|

Any release, discharge or settlement between the Buyer and F-star in relation
to this guarantee shall be conditional on no right, disposition or payment to
F-star by the Buyer, the Company or any other person in respect of the
Guaranteed Obligations being avoided, set aside or ordered to be refunded
under any enactment or law relating to breach of duty by any person,
bankruptcy, liquidation, administration, protection from creditors generally
or insolvency or for any other reason. 

| 
---|--- 

11.6.

|

If any right, disposition or payment referred to in clause 11.5 is avoided,
set aside or ordered to be refunded, F-star shall be entitled subsequently to
enforce this guarantee against the 

 

 
--- 
| | 

CONFIDENTIAL

|

27

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

Buyer as if such release, discharge or settlement had not occurred and any
such right, security, disposition or payment had not been given or made.

| 
---|--- 

11.7.

|

F-star shall be entitled to enforce this clause 11 against the Buyer as if it
were a party to this Agreement. 

| 
---|--- 

12.

|

SELLERS' REPRESENTATIVE 

| 
---|--- 

12.1.

|

Each Seller hereby irrevocably and unconditionally appoints the Sellers'
Representative as sole representative agent and attorney-in-fact to act on
such Seller's behalf for all purposes relating to this Agreement after
Completion and each agreement and document ancillary thereto, including for
the purposes of: 

| 
---|--- 

(a)

|

accepting and giving notices on behalf of such Seller; 

| 
---|--- 

(b)

|

making elections and granting any consent or approval on behalf of such Seller
under this Agreement; 

| 
---|--- 

(c)

|

approving and executing any document on behalf of such Seller to give effect
to the release of any money then standing to the credit of the Escrow Account; 

| 
---|--- 

(d)

|

defending, negotiating, compromising, settling and releasing on behalf of such
Seller any rights and claims (including legal proceedings) which the Buyer may
threaten or pursue in respect of any breach of, or right under, this Agreement
or any other Transactional Document; 

| 
---|--- 

(e)

|

confirming the allocation between the Sellers of the Contingent Consideration
to be made under this Agreement; 

| 
---|--- 

(f)

|

enforcing, negotiating, compromising, settling and releasing on behalf of such
Seller any rights and claims (including legal proceedings and ADR) which he
may have, threaten or pursue against the Buyer (or any other person) in
respect of any breach of, or right under, this Agreement or any other
Transactional Document or any Dispute; 

| 
---|--- 

(g)

|

consent or agree to any amendment to this Agreement or to waive any terms and
conditions of this Agreement providing rights or benefits to the Sellers
(other than with respect to the payment of the Total Consideration) in
accordance with the terms hereof and in the manner provided herein; 

| 
---|--- 

(h)

|

taking any and all actions that may be necessary or desirable in connection
with the payment by the Sellers of the costs and expenses incurred under this
Agreement; and 

 

 
--- 
| | 

CONFIDENTIAL

|

28

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

(i)

|

generally taking any and all other actions and doing any and all other things
provided in or contemplated by this Agreement and each agreement and document
ancillary thereto to be performed by such Seller or the Sellers'
Representative. 

| 
---|--- 

12.2.

|

Each Seller hereby irrevocably (by way of security for the performance of his
obligations under this Agreement) appoints the Sellers' Representative as its
agent with full authority on his behalf and in the Seller's name, as
applicable, or otherwise, to do all acts and to execute and deliver such
documents or deeds as are required by law or as may, in the reasonable opinion
of the Sellers' Representative, be required or convenient to give effect to
the matters described in clause 12.1. 

| 
---|--- 

12.3.

|

The Sellers' Representative shall act in good faith in accordance with what
the Sellers' Representative believes to be the best interests of the Sellers
when exercising any power or authority conferred on under this clause 12. 

| 
---|--- 

12.4.

|

Save in the event of fraud, any action undertaken or omitted by the Sellers'
Representative with the written approval of a Sellers' Majority shall be
conclusively deemed to be in accordance with the requirements of clause 12.3
provided that, for the avoidance of doubt, such approval shall not be
necessary. 

| 
---|--- 

12.5.

|

The Sellers' Representative may resign at any time. The Sellers'
Representative may consult with any Seller to the extent a claim is threatened
or pursued by the Buyer in respect of any breach of, or right under, this
Agreement or any other Transactional Document and which specifically concerns
any actual or alleged act or default of that Seller. 

| 
---|--- 

12.6.

|

The Sellers may, by written notice signed by a Sellers Majority (a "Change Of
Sellers' Representative Notice"), replace a resigning Sellers' Representative
or remove an incumbent Sellers' Representative from such position and appoint
another person to act as Sellers' Representative in substitution thereof (a
"New Sellers' Representative"). A Change Of Sellers' Representative Notice
shall be effective only once a copy thereof has been served on both the
incumbent Sellers' Representative and the Buyer. 

| 
---|--- 

12.7.

|

A New Sellers' Representative so appointed shall, with effect from the time of
its appointment, execute a deed of adherence in favour of the Sellers and the
Buyer pursuant to which it shall agree to adhere to, and be bound by, this
Agreement as though named herein as the Sellers' Representative and the
parties agree that such substitute New Sellers' Representative shall be
conferred the rights, power and authorities (including as set out in this
clause 12) of the Sellers' Representative as set out in this Agreement and
entitled to directly enforce the same (notwithstanding that it may not have
initially been a signatory hereto). A copy of such deed of adherence shall be
delivered to the Buyer at the same time as the Change Of Sellers'
Representative Notice is served thereon under clause 12.6. 

 

 
--- 
| | 

CONFIDENTIAL

|

29

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

12.8.

|

If at any time a New Sellers' Representative is appointed in accordance with
clause 12.6, if required by the Buyer, the Sellers' Representative hereby
undertakes to do all such things as may be necessary to novate the Escrow
Agreement from the previous Sellers' Representative to the New Sellers'
Representative. 

| 
---|--- 

12.9.

|

Any action taken or any exercise of powers under this Agreement by the
Sellers' Representative or any New Sellers' Representative shall be binding on
each Seller for the purposes of this Agreement, shall be deemed to be done by
each Seller, and the Buyer shall be entitled to assume that any action taken
by the Sellers' Representative or any New Sellers' Representative whose
appointment has been notified in accordance with this clause 14 is binding on
all of the Sellers and the parties shall be entitled to rely on the same. The
Buyer shall not be required to make further enquiries in respect thereof. The
Buyer shall have no obligation to monitor or supervise the Sellers'
Representative or any New Sellers' Representative. The Buyer shall not be
liable to any of the Sellers for any action taken or omitted to be taken by
the Sellers' Representative or any New Sellers' Representative. 

| 
---|--- 

12.10.

|

All costs (including legal costs) and expenses (including Tax), in each case,
of any nature whatsoever, of the Sellers' Representative shall be borne by the
Sellers in the proportions set out in column D of the table in Schedule 1 (The
Sellers). 

| 
---|--- 

12.11.

|

The Sellers' Representative shall have no liability or obligation to take any
action on behalf of any Seller under the powers and authorities conferred on
the Sellers' Representative by this Agreement where such action may result in
the Sellers' Representative incurring any cost, expense or liability unless
the Sellers' Representative is satisfied with any arrangements made by (or on
behalf of) the Sellers for the satisfaction or re-imbursement of such costs,
expenses and liabilities. 

| 
---|--- 

12.12.

|

Upon Completion, and subject to receipt by the Sellers' Representative of the
cash sum provided for in clause 3.3(a), the Sellers' Representative will
retain an amount of [***] from such sum (the "Expense Fund"), which will be
used for the purposes of paying directly, or reimbursing the Sellers'
Representative for, any third party expenses pursuant to this Agreement and
the transactions contemplated hereby. The Sellers will not receive any
interest or earnings on the Expense Fund and irrevocably transfer and assign
to the Sellers' Representative any ownership right that they may otherwise
have had in any such interest or earnings. The Sellers' Representative will
not be liable for any loss of principal of the Expense Fund other than as a
result of its gross negligence or wilful misconduct. The Sellers'
Representative will hold these funds separate from its corporate funds in a
segregated client account, will not use these funds for its operating expenses
or any other corporate purposes and will not voluntarily make these funds
available to its creditors in the event of bankruptcy. As soon as practicable
following the completion of the Sellers' Representative's responsibilities,
the Sellers' Representative will distribute the balance of the Expense Fund 

 

 
--- 
| | 

CONFIDENTIAL

|

30

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

to the Payments Administrator for further distribution to the Sellers. For tax
purposes, the Expense Fund shall be treated as having been received and
voluntarily set aside by the Sellers at the time of Completion. The parties
agree that the Sellers' Representative is not responsible for any tax
withholding or reporting or acting as a withholding agent or in any similar
capacity in connection with the Expense Fund.

| 
---|--- 

12.13.

|

The Sellers' Representative will incur no liability of any kind with respect
to any action or omission by the Sellers' Representative in connection with
Sellers' Representative's services pursuant to this Agreement and any
agreements ancillary hereto, except in the event of liability directly
resulting from the Sellers' Representative's gross negligence or wilful
misconduct. The Sellers' Representative shall not be liable to any Seller as a
result of any action or omission that is taken (or not taken) in good faith
pursuant to the advice of external legal counsel in the proper performance of
its obligations under this Agreement. The Sellers will, severally and not
jointly, on a pro rata basis equal to the portion of Total Consideration each
such Seller is entitled to receive pursuant to this Agreement compared to the
aggregate Total Consideration entitled to be received by all Sellers,
indemnify, defend and hold harmless the Sellers' Representative from and
against any and all losses, liabilities, damages, claims, penalties, fines,
forfeitures, actions, fees, costs and expenses (including the fees and
expenses of counsel and experts and their staffs and all expense of document
location, duplication and shipment) (collectively, "Representative Losses")
arising out of or in connection with the Sellers' Representative's execution
and performance of this Agreement and any agreements ancillary hereto, in each
case as such Representative Loss is suffered or incurred; provided, that in
the event that any such Representative Loss is finally adjudicated to have
been directly caused by the gross negligence or wilful misconduct of the
Sellers' Representative, the Sellers' Representative will reimburse the
Sellers the amount of such Representative Loss to the extent attributable to
such gross negligence or wilful misconduct. If not paid directly to the
Sellers' Representative by the Sellers, any such indemnified Representative
Losses may be recovered by the Sellers' Representative from (i) the funds in
the Expense Fund, (ii) the amounts in the Escrow Amount at such time as
remaining amounts would otherwise be distributable to the Sellers, and (iii)
from any Milestone Payments at such time as any such amounts would otherwise
be distributable to the Sellers; provided, that while this section allows the
Sellers' Representative to be paid from the Expense Fund, the Escrow Amount
and the Milestone Payments, this does not relieve the Sellers from their
obligation to promptly pay such Representative Losses as they are suffered or
incurred, nor does it prevent the Sellers' Representative from seeking any
remedies available to it at law or otherwise. In no event will the Sellers'
Representative be required to advance its own funds on behalf of the Sellers
or otherwise. For the avoidance of doubt and notwithstanding anything in this
Agreement to the contrary, the limitations on liability of the Sellers set
forth elsewhere in this Agreement are not intended to be applicable 

 

 
--- 
| | 

CONFIDENTIAL

|

31

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

to the indemnities provide to the Sellers' Representative under this clause
12.13. The Sellers acknowledge and agree that the foregoing indemnities will
survive the resignation or removal of the Sellers' Representative or the
termination of this Agreement.

| 
---|--- 

13.

|

PAYMENTS 

| 
---|--- 

13.1.

|

Payments to be made to the Sellers under this Agreement shall be made in US
dollars by telegraphic transfer of immediately available funds to such account
controlled by the Payments Administrator as may be notified by the Payments
Administrator or the Sellers' Representative in writing to the Buyer. 

| 
---|--- 

13.2.

|

Payments to be made to the Buyer under this Agreement shall be made in US
dollars by telegraphic transfer of immediately available funds to such account
as may be notified in writing by the Buyer to the Payments Administrator. 

| 
---|--- 

13.3.

|

The payment of any sum to the Buyer by or on behalf of any of the Sellers will
discharge the obligations of the Sellers to pay the sum in question and the
Sellers shall not be concerned to see the application of the monies so paid. 

| 
---|--- 

13.4.

|

The payment of any sum to the Payments Administrator by or on behalf of the
Buyer will discharge the obligations of the Buyer to pay the sum in question
and the Buyer shall not be concerned to see the application of the monies so
paid. 

| 
---|--- 

14.

|

ANNOUNCEMENTS 

| 
---|--- 

14.1.

|

Subject to clause 14.2, no party (the "disclosing party") may, before or after
Completion, make or issue a public announcement or press release concerning
the transactions referred to in this Agreement other than the Press Release
unless it has first obtained the written consent of the Sellers (prior to
Completion, if the disclosing party is the Buyer) or the Sellers'
Representative (after Completion, if the disclosing party is the Buyer), or of
the Buyer (if the disclosing party is a Seller) (in either case, the "other
party"), which consent may not be unreasonably withheld or delayed. 

| 
---|--- 

14.2.

|

Clause 14.1 does not apply to a public announcement or press release required
by law, by a rule of a listing authority by which a party's shares are listed,
a stock exchange on which a party's shares are listed or traded or by a
governmental authority or other authority with relevant powers to which either
party is subject or submits, whether or not the requirement has the force of
law, provided that the public announcement, communication or circular shall so
far as is practicable be made after consultation with the other party and
after taking into account the reasonable requirements of the other party as to
its timing, content and manner of making or despatch. 

 

 
--- 
| | 

CONFIDENTIAL

|

32

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

15.

|

CONFIDENTIALITY 

| 
---|--- 

15.1.

|

Subject to clause 15.4, each party shall treat the following information as
confidential to the extent obtained as a result of or in connection with
entering into this Agreement: 

| 
---|--- 

(a)

|

details of the provisions of this Agreement, the Transactional Documents and
any other agreement or arrangement entered into in connection with this
Agreement; 

| 
---|--- 

(b)

|

information relating to the negotiations leading to the execution of this
Agreement, the Transactional Documents and any other agreement or arrangement
entered into in connection with this Agreement; and 

| 
---|--- 

(c)

|

(to the extent obtained as a result of or in connection with entering into
this Agreement) information relating to the other party or such party's group
undertakings, 

provided that the parties shall always be permitted to confirm that the
transaction effected by this Agreement has taken place without providing any
further information.

| 
---|--- 

15.2.

|

Any party may disclose information otherwise required by clause 15.1 to be
treated as confidential: 

| 
---|--- 

(a)

|

if and to the extent required by the laws of any relevant jurisdiction,
provided that the disclosing party shall, where it is practicable to do so and
where permitted under applicable law, notify the other party of such
disclosure in writing and take reasonable steps to minimize the extent of any
such required disclosure; 

| 
---|--- 

(b)

|

if and to the extent requested by any competent regulatory or governmental
body, Tax Authority or securities exchange in any relevant jurisdiction
wherever situated, whether or not the request has the force of law and
including for the avoidance of doubt, any disclosure required by US accounting
regulations; 

| 
---|--- 

(c)

|

to a Tax Authority in connection with the Tax affairs of the disclosing party; 

| 
---|--- 

(d)

|

to its professional advisers, auditors or bankers from time to time provided
that such disclosure is reasonably required; 

| 
---|--- 

(e)

|

to its shareholders and/or its limited partners as appropriate; 

| 
---|--- 

(f)

|

in the case of the Buyer, to members of the Buyer's Group and to their
professional advisers, auditors or bankers in each case from time to time; 

| 
---|--- 

(g)

|

if and to the extent the information is or comes into the public domain
through no fault of that part of any of those to whom that party has disclosed
information; or 

 

 
--- 
| | 

CONFIDENTIAL

|

33

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

(h)

|

if and to the extent, in the case of a Seller, the Buyer or, in the case of
the Buyer, the Sellers' Representative, has given prior written consent to the
disclosure. 

| 
---|--- 

15.3.

|

Each party shall ensure that any person to whom confidential information is
disclosed pursuant to clauses 15.2(d) through 15.2(f) is made aware of the
obligations of confidentiality contained in this clause and agrees to adhere
to them. 

| 
---|--- 

15.4.

|

Notwithstanding anything in this Agreement to the contrary, following
Completion, the Sellers' Representative shall be permitted to: (i) after the
public announcement (if any) of the transaction contemplated by this
Agreement, publicly announce that it has been engaged to serve as the Sellers'
Representative in connection with the transaction as long as such announcement
does not disclose any of the other terms hereof and (ii) disclose information
to the Sellers who have a need to know such information provided that any such
information will be subject to the confidentiality provisions of this
Agreement including clause 15.1. 

| 
---|--- 

16.

|

COSTS 

Except where this Agreement or the relevant document provides otherwise, each
party shall pay its own costs relating to the negotiation, preparation,
execution and performance by it of this Agreement and of each document
referred to in it.

| 
---|--- 

17.

|

GENERAL 

| 
---|--- 

17.1.

|

A variation of this Agreement is valid only if it is in writing and signed by
or on behalf of each party, provided that after Completion, any variation may
be signed by the Sellers' Representative on behalf of itself and the Sellers
provided the Sellers' Representative has the prior written approval of the
Sellers Majority. The parties to this Agreement do not require the consent of
any person having a right under the Contracts (Rights of Third Parties) Act
1999, as provided in clause 17.7, to rescind or vary this agreement. 

| 
---|--- 

17.2.

|

The failure to exercise or delay in exercising a right or remedy provided by
this Agreement or by law does not impair or constitute a waiver of the right
or remedy or an impairment of or a waiver of other rights or remedies. No
single or partial exercise of a right or remedy provided by this Agreement or
by law prevents further exercise of the right or remedy or the exercise of
another right or remedy. 

| 
---|--- 

17.3.

|

The Buyer's rights and remedies contained in this Agreement are cumulative and
not exclusive of rights or remedies provided by law to the extent not excluded
or limited by this Agreement. 

| 
---|--- 

17.4.

|

Except to the extent that they have been performed and except where this
Agreement provides otherwise, the obligations contained in this Agreement
remain in force after Completion. 

 

 
--- 
| | 

CONFIDENTIAL

|

34

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

17.5.

|

Any payment by a Seller, pursuant to a Fundamental Warranty Claim, Special
Indemnity Claim or Tax Warranty Claim or a Warrantor, pursuant to a Warrantor
Fundamental Warranty Claim or a Business Warranty Claim shall, to the extent
possible and without limiting the liability of any Seller or Warrantor (as the
case may be) under this Agreement, be treated as a reduction in the purchase
price payable by the Buyer for the Shares. 

| 
---|--- 

17.6.

|

All payments made by a Seller under this Agreement shall be made gross, free
of right of counterclaim or set off and without deduction or withholding of
any kind other than deductions or withholding required by law. 

| 
---|--- 

17.7.

|

Except as provided in clauses 10.7 and 11.7, a person who is not a party to
this Agreement has no right, including under the Contracts (Rights of Third
Parties) Act 1999 to enforce any term of this Agreement. 

| 
---|--- 

18.

|

ENTIRE AGREEMENT 

| 
---|--- 

18.1.

|

The Transactional Documents constitute the entire agreement between the
parties. They supersede any previous agreements relating to the subject matter
of the Transactional Documents, and set out the complete legal relationship of
the parties arising from or connected with that subject matter. 

| 
---|--- 

18.2.

|

Nothing in this clause 19 shall have the effect of limiting any liability
arising from fraud or wilful non-disclosure. 

| 
---|--- 

19.

|

ASSIGNMENT 

| 
---|--- 

19.1.

|

Subject to clause 19.2, no right or obligation arising under this Agreement or
any other Transactional Document may be assigned, transferred or otherwise
disposed of, in whole or in part without the prior written agreement if the
assignor is the Buyer, of the Sellers' Representative, or if the assignor is a
Seller, of the Buyer. 

| 
---|--- 

19.2.

|

The Buyer shall be entitled to assign any benefit arising under or out of this
Agreement or any other Transactional Document to any Buyer's Group Undertaking
provided that the Buyer enters into a guarantee in a form reasonably
satisfactory to the Sellers' Representative and further provided that, if the
assignee is to cease to be a Buyer's Group Undertaking it shall, before
ceasing to be so, assign the benefit (so far as it is assigned) to another
Buyer's Group Undertaking. 

| 
---|--- 

19.3.

|

The Buyer agrees that if it makes an assignment pursuant to this clause 19,
the assignment shall not increase the liabilities of any Seller. 

 

 
--- 
| | 

CONFIDENTIAL

|

35

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

| 
---|--- 

20.

|

NOTICES 

| 
---|--- 

20.1.

|

A notice or other communication under or in connection with this Agreement (a
"Notice") shall be: 

| 
---|--- 

(a)

|

in writing; 

| 
---|--- 

(b)

|

in the English language; and 

| 
---|--- 

(c)

|

delivered personally or sent by first class post (and air mail if overseas) or
fax or email to the party due to receive the Notice to the address set out in
clause 20.3 or to an alternative address, person or fax number or email
address specified by that party by not less than five Business Days' written
notice to the other party received before the Notice was despatched. 

| 
---|--- 

20.2.

|

Unless there is evidence that it was received earlier, a Notice is deemed
given if: 

| 
---|--- 

(a)

|

delivered personally, when left at the address referred to in clause 20.3; 

| 
---|--- 

(b)

|

sent by mail, except air mail, two Business Days after posting it; 

| 
---|--- 

(c)

|

sent by air mail, six Business Days after posting it; and 

| 
---|--- 

(d)

|

sent by email, when the email is sent, provided that a copy of the Notice is
sent by another method referred to in this clause 20.2 on the same Business
Day as the sending of the email, and provided further that the sender of the
email does not receive an automated response from the recipient or a mail
server indicating that the recipient is out of office or that the email could
not be delivered. 

| 
---|--- 

20.3.

|

The address referred to in clause 23.1.3 is: 

 

 
--- 
| | 

CONFIDENTIAL

|

36

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

 
--- 
| | | | 

Name of Party

|

Address

|

Email address or telephone number

|

For the attention of 

|

|

| 

Each Seller

|

In relation to each Seller, the address set out adjacent to that Seller's name
in column A of Schedule 1 (The Sellers). 

|

|

| 

Seller\'s Representative

|

Shareholder Representative Services LLC

1614 15th Street, Suite 200, Denver, CO 80202, United States

|

deals@srsacquiom.com

|

Managing Director 

|

|

| 

The Buyer

|

201 Gateway Boulevard

South San Francisco

California

United States

|

[***]

|

Nick Galli and Alexander Schuth 

|

|

| 

| 
---|--- 

21.

|

COUNTERPARTS 

This Agreement may be executed in any number of counterparts, each of which
when executed and delivered is an original and all of which together evidence
the same agreement.

| 
---|--- 

22.

|

GOVERNING LAW 

This Agreement or the performance, enforcement, breach or termination hereof
shall be interpreted, governed by and construed in accordance with the laws of
England, excluding any conflicts or choice of law rule or principle that might
otherwise refer construction or interpretation of this Agreement to the
substantive law of another jurisdiction.

| 
---|--- 

23.

|

DISPUTE RESOLUTION 

| 
---|--- 

23.1.

|

If a dispute arises between the Parties in connection with or relating to this
Agreement or any document or instrument delivered in connection herewith (a
"Dispute"), it shall be resolved pursuant to this clause 23. 

| 
---|--- 

23.2.

|

General 

Any Dispute shall first be referred to the Chief Executive Officer of the
Buyer and the Sellers' Representative, who shall confer in good faith on the
resolution of the issue. Any final decision mutually agreed to by such persons
shall be conclusive and binding on the parties to this Agreement. If such
persons are not able to agree on the resolution of any such


 

--- 
| | 

CONFIDENTIAL

|

37

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

issue within thirty (30) days (or such other period of time as mutually agreed
by the Buyer and the Seller's Representative) after such issue was first
referred to them, then either the Buyer or the Sellers' Representative may, by
written notice to the other, elect to initiate an alternative dispute
resolution ("ADR") proceeding pursuant to the procedures set forth in clause
23.3 for purposes of having the matter settled.

| 
---|--- 

23.3.

|

ADR 

Any ADR proceeding under this Agreement (with the exception of that specified
in paragraph 11 of Schedule 8) shall take place pursuant to the procedures set
forth in clause 15.7.3 of the License Agreement, save that references to
"Denali" are references to the Buyer and references to the "Licensor" are
references to the Sellers (or relevant Seller).

| 
---|--- 

23.4.

|

Interim Relief 

Notwithstanding anything herein to the contrary, nothing in this clause 23
shall preclude either party from seeking interim or provisional relief,
including a temporary restraining order, preliminary injunction or other
interim equitable relief concerning a Dispute following the ADR procedures set
forth in clause 23.3, if necessary to protect the interests of such party.
This clause shall be specifically enforceable.

| 
---|--- 

23.5.

|

RIGHTS OF EACH PARTY/NON-WAIVER 

The rights of each party under this Agreement:

| 
---|--- 

(a)

|

may be exercised as often as necessary; 

| 
---|--- 

(b)

|

except as otherwise expressly provided in this Agreement, are cumulative and
not exclusive of rights and remedies provided by law; and 

| 
---|--- 

(c)

|

may be waived only in writing and specifically. 

| 
---|--- 

24.

|

PROCESS AGENTS 

The Buyer irrevocably appoints [***] as its process agent to receive on its
behalf service of process in any proceedings [***]. Service upon the process
agent shall constitute good and valid service on the Buyer whether or not the
process is forwarded to or received by the Buyer. If for any reason the
process agent ceases to act as process agent, resigns [***], the Buyer
irrevocably agrees to appoint a substitute process agent [***] acceptable to
the Sellers' Representative and to deliver to the Sellers' Representative a
copy of the substitute process agents' acceptance of that appointment within
10 Business Days of the obligation to appoint arising. In the event that the
Buyer fails to appoint a substitute process agent, it shall be


 

--- 
| | 

CONFIDENTIAL

|

38

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

effective service for the Sellers (or the Sellers' Representative) to serve
process upon the last known address [***] of the last known process agent for
the Buyer notified to the Sellers, notwithstanding that such process agent is
no longer found at such address or has ceased to act.

| 
---|--- 

25.

|

CONFLICT WAIVER 

Notwithstanding that the Company has been represented by Cooley (UK) LLP (the
"Firm") in the preparation, negotiation and execution of this Agreement and
the transactions contemplated hereby, the Company agrees that after Completion
the Firm may represent the Sellers' Representative, the Sellers and/or their
Affiliates in matters related to this Agreement and the transactions
contemplated hereby, including without limitation in respect of any
indemnification claims pursuant to this Agreement and the transactions
contemplated hereby. The Company hereby acknowledges, on behalf of itself and
its Affiliates, that it has had an opportunity to ask for and has obtained
information relevant to such representation, including disclosure of the
reasonably foreseeable adverse consequences of such representation, and it
hereby waives any conflict arising out of such future representation.

IT WITNESS whereof this Agreement has been entered into as a deed and is
delivered on the date first aforementioned.




 

--- 
| | 

CONFIDENTIAL

|

39

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

SCHEDULE 1

The Sellers 

--- 
| | | | | 

(A)

|

(B)

|

(C)

|

(D)

|

(E)

|

(F) 

Name and Address of Seller

|

No. of Ordinary Shares

|

No. of Deferred Shares

|

Proportion of Initial Consideration (%)

|

Contribution to Expense Fund (US$)

|

Contribution to Escrow Account (%) 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

[***]

|

[***]

|

[***]

|

[***]

|

[***]

|

[***] 

 

[***]




 

--- 
| | 

CONFIDENTIAL

|

40

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 

SCHEDULE 2

Information about the Company 

--- 
| 

Registered Number:

|

10214672 

| 

Place of Incorporation:

|

England and Wales 

| 

Address of Registered Office:

|

Eddeva B920

Babraham Research Campus

Cambridge CB22 3AT 

| 

Type of Company:

|

Private company limited by shares 

| 

Total Issued Share Capital:

|

Â£90.39625 comprising (i) 8,969,550 ordinary shares; and (ii) 70,075 deferred
shares, in each case with an aggregate nominal value of Â£0.00001 with Â£0.00001
paid up on each share 

| 

Directors:

|

John Edwards

Jean-Francois Formela

Deborah Harland

Tolga Hassan

John Haurum

Patrick Krol

Florian Ruker

Helmut Schuehsler 

| 

Secretary:

|

Tolga Hassan 

| 

Accounting Reference Date:

|

31 December 

| 

Subsidiaries:

|

None 

 


 

--- 
| | 

CONFIDENTIAL

|




SCHEDULE 3

Completion Requirements

| 
---|--- 

1.

|

Sellers' Obligations 

| 
---|--- 

1.1.

|

At Completion, each Seller shall deliver the following documents or items to
the Buyer or at the Buyer's direction: 

| 
---|--- 

1.1.1.

|

duly executed transfer(s) in respect of that Seller's Relevant Shares to the
Buyer or its nominee(s) and the share certificate(s) for such Relevant Shares; 

| 
---|--- 

1.1.2.

|

duly executed powers of attorney or other authorities in the agreed form under
which this Agreement, the other Transactional Documents and the transfers
referred to in paragraph 1.1.1 of this Schedule 3 have been or are to be
executed by such Seller; and 

| 
---|--- 

1.1.3.

|

(if the Buyer so requires) an irrevocable power of attorney in the agreed form
duly executed by such Seller and any other registered owner of such Seller's
Relevant Shares in favour of the Buyer or its nominee(s) generally in respect
of the Relevant Shares. 

| 
---|--- 

1.2.

|

At Completion the Sellers shall deliver, procure delivery or make available to
the Buyer: 

| 
---|--- 

1.2.1.

|

each register, minute book and other book required by law to be kept by the
Company made up to the Completion Date and each certificate of incorporation
and certificate(s) of incorporation on change of name for the Company; 

| 
---|--- 

1.2.2.

|

(if the Buyer so requires) resignations in the agreed form from each director
and secretary of the Company expressed to take effect from the end of the
meeting held pursuant to paragraph 1.3; 

| 
---|--- 

1.2.3.

|

the Management Accounts; 

| 
---|--- 

1.2.4.

|

a copy of each bank mandate of the Company and copies of statements of each
bank account of the Company made up to a date not earlier than two (2)
Business Days before the Completion Date; 

| 
---|--- 

1.2.5.

|

a counterpart of the Escrow Agreement duly executed by the Sellers'
Representative; and 

| 
---|--- 

1.2.6.

|

the Disclosure Letter signed on behalf of each Warrantor. 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

1.3.

|

The Sellers shall ensure that at Completion a meeting of the board of
directors of the Company is held at which the directors: 

| 
---|--- 

1.3.1.

|

vote in favour of the registration of the Buyer or its nominee(s) as member(s)
of the Company in respect of the Shares (subject to the production of properly
stamped transfers); and 

| 
---|--- 

1.3.2.

|

approve the payment of the Transaction Costs. 

| 
---|--- 

2.

|

Buyer's Obligations 

| 
---|--- 

2.1.

|

At Completion, the Buyer shall deliver to the Sellers: 

| 
---|--- 

2.1.1.

|

a counterpart of the Escrow Agreement duly executed by the Buyer; and 

| 
---|--- 

2.1.2.

|

a counterpart of the Disclosure Letter signed by the Buyer. 

| 
---|--- 

2.2.

|

At Completion, the Buyer shall procure that the Company shall pay the
Transaction Costs to the extent not already paid. 

 

 
--- 
| | 

CONFIDENTIAL

|




SCHEDULE 4

Completion Accounts

Part A: Preparation of Completion Accounts

| 
---|--- 

1.

|

The Buyer shall procure that Draft Completion Accounts are prepared in
accordance with the provisions of this Part A of Schedule 4 and on the basis
of the Accounting Policies. 

| 
---|--- 

2.

|

The Draft Completion Accounts shall be delivered to the Sellers'
Representative by the Buyer as soon as is reasonably practicable and, in any
event, not later than 90 calendar days after Completion. 

| 
---|--- 

3.

|

If the Sellers' Representative does not within 30 calendar days of
presentation to it of the Draft Completion Accounts give notice to the Buyer
that it disagrees with the Draft Completion Accounts or any item therein,
stating the reasons for the disagreement in reasonable detail including each
disputed item, the amount in dispute and the basis for such dispute (the
"Sellers' Disagreement Notice"), the Draft Completion Accounts shall
constitute the Completion Accounts and shall be final and binding on the
parties for all purposes in accordance with paragraph 12 of this Part A of
Schedule 4. 

| 
---|--- 

4.

|

If the Sellers' Representative gives a Sellers' Disagreement Notice under
paragraph 3, the Buyer and the Sellers' Representative shall attempt in good
faith to reach agreement in respect thereof (and, if such agreement is
reached, the Draft Completion Accounts as amended by the matters set out in
the Sellers' Disagreement Notice and agreed by the Buyer and the Sellers'
Representative in writing shall constitute the Completion Accounts and shall
be final and binding on them for all purposes in accordance with paragraph 12
of this Part A of Schedule 4). If they are unable to do so within 30 calendar
days of such notification under paragraph 3 of this Part A of Schedule 4,
either party may, by notice to the other (an "Appointment Notice"), require
that the Draft Completion Accounts be referred to an independent firm of
internationally recognised chartered accountants agreed upon by the Buyer and
the Sellers' Representative or, failing agreement within five (5) Business
Days of service of the Appointment Notice, nominated by the President for the
time being of the Institute of Chartered Accountants in England and Wales or
in his/her absence a suitable deputy (the "Reporting Accountants"). 

| 
---|--- 

5.

|

The Reporting Accountants shall be engaged jointly by the Buyer and the
Sellers (acting through the Sellers' Representative) and the charges
(including any VAT) of the Reporting Accountants shall be allocated between
the Buyer on the one hand and the Sellers (acting through the Sellers'
Representative) on the other by the Reporting Accountants in proportion 

 

 
--- 
| | 

CONFIDENTIAL

|


to the extent either of such parties did not prevail in the aggregate on the
disputed items (as measured by the amounts in dispute). If any amount is
payable by the Sellers pursuant to this paragraph 5, such amount shall be paid
from the Escrow Account when the Buyer and the Sellers' Representative shall
within three (3) Business Days following the date of such election or within
five (5) Business Days of the Determination Date (whichever is later) jointly
instruct the Escrow Agent in writing to make such payment out of amounts
standing to the credit of the Escrow Account.

| 
---|--- 

6.

|

Except to the extent that the Buyer and the Sellers' Representative agree
otherwise, the Reporting Accountants shall determine their own procedure but
each party shall use all reasonable endeavours to procure that the Reporting
Accountants apply the following rules: 

| 
---|--- 

6.1.

|

apart from procedural matters and as otherwise set out in this Agreement, they
shall determine only: 

| 
---|--- 

6.1.1.

|

whether any of the arguments for an alteration to the Draft Completion
Accounts put forward in respect of matters specified in the Sellers'
Disagreement Notice is correct in whole or in part (unless such matters have
been agreed between the Sellers' Representative and the Buyer); and 

| 
---|--- 

6.1.2.

|

if so, what alterations (if any) should be made to the Draft Completion
Accounts; 

| 
---|--- 

6.2.

|

they shall apply the Accounting Policies; 

| 
---|--- 

6.3.

|

they shall make their determination pursuant to paragraph 6.1 of this Part A
of Schedule 4 as soon as is reasonably practicable; 

| 
---|--- 

6.4.

|

the procedure of the Reporting Accountants shall: 

| 
---|--- 

6.4.1.

|

give the Buyer and the Sellers' Representative a reasonable opportunity to
make oral representations and representations in writing to them; 

| 
---|--- 

6.4.2.

|

require that each party supplies the other with a copy of any representations
in writing at the same time as they are made to the Reporting Accountants; and 

| 
---|--- 

6.4.3.

|

permit each party to be present while oral submissions are being made by the
other party; 

| 
---|--- 

6.5.

|

for the avoidance of doubt, the Reporting Accountants shall not be entitled to
determine the scope of their own jurisdiction; and 

| 
---|--- 

6.6.

|

the determination of the Reporting Accountants pursuant to paragraph 6.1 of
this Part A of Schedule 4 shall be made in writing. 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

7.

|

The Reporting Accountants shall act as experts and not as arbitrators and
their determination of any matter falling within their jurisdiction shall be
final and binding on the parties, save in the event of fraud of the Buyer, any
of the Sellers or the Reporting Accountants or manifest error of the Reporting
Accountants (when the relevant part of their determination shall be void). In
particular, without limitation, their determination shall be deemed to be
incorporated into the Draft Completion Accounts, which shall then be final and
binding on the parties for the purposes of this Schedule 4, save as stated
above in the event of fraud or manifest error. 

| 
---|--- 

8.

|

The Buyer and the Sellers' Representative shall co-operate with the Reporting
Accountants and comply with their reasonable requests made in connection with
the carrying out of their duties pursuant to their engagement under the terms
of this Agreement. 

| 
---|--- 

9.

|

Subject to paragraph 10 of this Part A of Schedule 4, nothing in this Schedule
4 shall entitle the Buyer or the Sellers' Representative or the Reporting
Accountants to have access to any information or document which is protected
by legal professional privilege, or which has been prepared by the other party
or its accountants or other professional advisers with a view to assessing the
merits of any claim or argument. 

| 
---|--- 

10.

|

The Buyer and the Sellers' Representative shall not be entitled by reason of
paragraph 9 of this Part A of Schedule 4 to refuse to supply such part or
parts of documents as contain only the facts on which the relevant claim or
argument is based. 

| 
---|--- 

11.

|

Each party and the Reporting Accountants shall, and shall procure that its
accountants and other advisers shall, keep all information and documents
provided to them pursuant to this Part A of Schedule 4 confidential and shall
not use them for any purpose, except for disclosure or use in connection with
the preparation of the Draft Completion Accounts and the agreement or
determination of the Completion Accounts, the proceedings of the Reporting
Accountants or any other matter arising out of this Agreement or in defending
any claim or argument or alleged claim or argument relating to this Agreement
or its subject matter. 

| 
---|--- 

12.

|

When the Sellers' Representative and the Buyer reach agreement on the Draft
Completion Accounts or when the Draft Completion Accounts is finally
determined at any stage in accordance with the procedures set out in this Part
A of Schedule 4: 

| 
---|--- 

12.1.

|

the Draft Completion Accounts as so agreed or determined shall constitute the
Completion Accounts for the purposes of this Agreement and shall (in the
absence of fraud or manifest error) be final and binding on the parties; and 

| 
---|--- 

12.2.

|

the "Actual Net Cash" shall be the amount set out in line item "E" in the
Completion Accounts. 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

13.

|

Subject to paragraph 9 of this Part A of Schedule 4 and clause 15 of the
Agreement, each Seller shall (in relation to information in its possession or
control only) and the Buyer shall procure that the Company shall (in relation
to information in their respective possession or control), promptly provide
the parties, their respective advisers, the Buyer's accountants and the
Sellers' accountants and, if relevant, the Reporting Accountants with all
information (in their respective possession or control) relating to the
operations of the Company, as the case may be, including access at all
reasonable times to the Company and the employees of the Company (who shall
give such explanations as any party may reasonably require in relation to the
preparation of the Draft Completion Accounts), books, records, and other
relevant information and all cooperation and assistance, as in any such case
be reasonably required to enable the production and agreement or determination
of the Completion Accounts pursuant to and in accordance with this Part A of
Schedule 4; provided however, that the auditors or accountants of the Buyer or
the Company shall not be obliged to make any work papers available to any
person unless and until such person has signed a customary agreement relating
to access to such work papers in form and substance reasonably acceptable to
the Buyer and such auditors or accountants. 

| 
---|--- 

14.

|

The Sellers (acting through the Seller's Representative) and the Buyer shall
each bear their own costs (including legal costs) and expenses (including tax)
together with VAT charged thereon, arising out of the preparation and review
of the Draft Completion Accounts and the agreement or determination of the
Completion Accounts. 

 

 
--- 
| | 

CONFIDENTIAL

|




Part B: Completion Accounts


 

--- 
| | 

|

|

[***] 

|

[***]

| 

[***]

|

[***]

| 

[***]

|

[***]

| 

[***]

|

[***]

| 

[***]

|

[***]

| 

[***]

|

[***]

| 

 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|




Part C: Accounting Policies

| 
---|--- 

1.

|

General Accounting Policies 

| 
---|--- 

1.1.

|

The Completion Accounts shall be determined in accordance with the following: 

| 
---|--- 

(a)

|

first, in accordance with the [***]; 

| 
---|--- 

(b)

|

secondly, and to the extent not covered by or inconsistent with paragraph
1.1(a) of this Part C of Schedule 4 (which shall prevail in the event of any
inconsistency), on a basis consistent with [***]; and 

| 
---|--- 

(c)

|

thirdly, and to the extent not covered by or inconsistent with paragraphs
1.1(a) or 1.1(b) of this Part C of Schedule 4 (which shall prevail in the
event of any inconsistency), [***]. 

| 
---|--- 

1.2.

|

The parties acknowledge that the sole purpose of determining the Actual Net
Cash is to determine the adjustments (if any) to be made to the Initial
Consideration in accordance with clause 3. 

| 
---|--- 

1.3.

|

The provisions of this Part C of Schedule 4 and the line items comprising the
Completion Accounts shall be interpreted so as to avoid double counting
(whether positive or negative) of any items to be included in the Actual Net
Cash. 

 



*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.




 

--- 
| | 

CONFIDENTIAL

|




Part D: Preparation of Management Accounts 

--- 

1\. ACCOUNTING POLICIES 

a. PRESENTATION OF MANAGEMENT ACCOUNTS 

CRITICAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY 

In the application of the Company\'s accounting policies, management make
judgments, estimates and assumptions about the carrying amounts of assets and
liabilities that are not readily apparent from other sources. The estimates
and associated assumptions are based on historical experience and other
factors that are considered to be relevant. Actual results may differ from
these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis.
Revisions to accounting estimates are recognised in the period of the revision
and future periods if the revision affects both current and future periods. 

--- 

b. OVERALL CONSIDERATIONS

The principal accounting policies adopted in the preparation of the management
accounts are set out below. 

i. BASIS OF PREPARATION OF MANAGEMENT ACCOUNTS 

These management accounts have been prepared in accordance with EU endorsed
International Financial Reporting Standards (IFRS) and interpretations issued
by the IFRS Interpretations Committee (IFRS IC) and the Companies Act 2006
applicable to companies reporting under IFRS. The management accounts have
been prepared under the historical cost convention.

| 
---|--- 

ii.

|

GOING CONCERN 

Management prepare management accounts on a going concern basis unless they
intend to liquidate the business or to cease trading, or have no realistic
alternative but to do so. In deciding whether the going concern basis is
appropriate, the directors examine existing budgets and forecasts, assess
borrowing requirements, and review other information as needed. 

--- 

iii. NEW AND AMENDED STANDARDS ADOPTED BY THE COMPANY 

In any period, new or amended standards and interpretations are considered for
adoption. Other standards, amendments and interpretations which are effective
for the period are considered where they material to the Company.




 

--- 
| | 

CONFIDENTIAL

|

 

--- 

c. RECEIVABLES 

Receivables are recognised initially at fair value less provision for
impairment. The Company provides an allowance for uncollectible accounts based
on prior experience and management's assessment of the collectability of
existing specific accounts.

| 
---|--- 

d.

|

CASH AND CASH EQUIVALENTS 

Cash and cash equivalents comprises cash on hand and demand deposits, and
other shortâterm and highly liquid investments with original maturities of
three months or less that are readily convertible to a known amount of cash
and are subject to an insignificant risk of changes in value. 

--- 

e. EQUITY AND RESERVES 

 

Ordinary and preferred shares are classified as equity. Issued capital
represents the nominal value of shares that have been issued. Retained
earnings includes all current period retained profits and accumulated losses.



| 
---|--- 

f.

|

TRADE PAYABLES 

Trade payables are obligations to pay for goods or services that have been
acquired in the ordinary course of business from suppliers. Trade and other
payables are stated at cost, which approximates fair value due to the short
term nature of these liabilities. Trade payables are classified as current
liabilities if payment is due within one period or less. If not, they are
presented as non-current liabilities.



| 
---|--- 

g.

|

REVENUE RECOGNITION 

 

Revenue is measured at the fair value of the consideration received or
receivable and is stated net of value added taxes. Revenue is recognised when
it is probable that future economic benefits will flow to the Company and
those benefits can be measured reliably. Revenue on the sale of an asset (e.g.
the outright sale or assignment of a licence) is only recognised when, inter
alia, the significant risks and rewards of ownership have been transferred to
the buyer and the Company does not retain either control of the goods, or
continuing involvement, to the degree associated with ownership.

Where, as part of a licence agreement, services are performed by an
indeterminate number of acts over a specified period of time, revenue for such
services is recognised on a straight-line basis over the specified period
unless there is evidence that some other method represents better the stage of
completion.

h. SHARE BASED PAYMENTS




 

--- 
| | 

CONFIDENTIAL

|


A share option compensation charge is not recognised in the monthly management
accounts.



| 
---|--- 

i.

|

TAXATION AND DEFERRED TAX 

A tax credit or charge is not reflected in the monthly management accounts.

Deferred tax is not reflected in the monthly management accounts.

| 
---|--- 

j.

|

FINANCIAL INSTRUMENTS 

| 
---|--- 

i.

|

FINANCIAL ASSETS 

All financial assets relate to trade and other receivables, which are stated
at their recoverable amount, which approximates the fair value due to the
short term nature of these assets. 

--- 

ii. RISK MANAGEMENT POLICY 

The Company undertakes transactions denominated in foreign currencies and as
such is exposed to currency risk due to fluctuations in foreign exchange
rates. The Company does not use derivative instruments to reduce exposure to
foreign exchange risk. 

--- 

iii. FINANCIAL LIABILITIES 

Trade and other payables are stated at cost. This approximates fair value due
to the short term nature of these liabilities.

| 
---|--- 

k.

|

FOREIGN CURRENCY TRANSLATION 

Foreign currency transactions are translated at the rates of exchange in
effect at the dates of the transaction. Resulting foreign currency denominated
monetary assets and liabilities are translated at the rates of exchange in
effect at the balance sheet date. Gains and losses on foreign exchange are
recognised in the income statement.








 

--- 
| | 

CONFIDENTIAL

|




SCHEDULE 5

Contingent Consideration

Part A: Contingent Consideration

| 
---|--- 

1.

|

Definitions 

In this Schedule 5, and where applicable, the remainder of this Agreement, the
following definitions shall apply:

"Accepted Fcab Target" has the meaning given to it in the License Agreement,
with respect to events and circumstances before Completion and has the meaning
given to it in the Gamma IP License with respect to events and circumstances
after Completion;

"Commercialisation" has the meaning given to it in the License Agreement;

"Commercially Reasonable Efforts" has the meaning given to it in the License
Agreement;

"Conforming mAb2" means [***];

"Contingent Consideration" means any of the Milestone Payments;

"Default Notice" has the meaning given to it in paragraph 2.2 of this Part A
of Schedule 5;

"Denali Fcab" has the meaning given to it in the License Agreement;

"EU Regulatory Milestone" means [***];

"European Union" or "E.U." has the meaning given to it in the License
Agreement and shall be deemed to include [***];

"Fcab Delivery" means, with respect to an Accepted Fcab Target, that an Fcab
that specifically binds to such Accepted Fcab Target has achieved "Fcab
Delivery" (as defined therein) under Section 4.3 or Section 9.11.1 of the
License Agreement or Section 4.1.2 of the Gamma Services Agreement during the
applicable Fcab Disclosure Period (as defined therein);



*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|


"First Commercial Sale" has the meaning given to it in the License Agreement,
except that all references to Licensed Products in such definition will be
read as references to mAb2 Products;

"Fcab" has the meaning given to it in the License Agreement;

"Fcab Disclosure Period" has the meaning given to it in Section 1.3.3 of that
certain letter agreement between the Company, F-Star, F-Star GmbH and Buyer
dated and entered into on or about May ___, 2018;

"GMP" has the meaning given to it in the License Agreement;

"Initial Milestone" has the meaning given to it in the table in Part B of this
Schedule 5;

"Initial Payment True Up Event" means that [***];

"Joint Fcab" has the meaning given to it in the License Agreement;

"Licensor Fcab" has the meaning given to it in the License Agreement;

"mAb2 Product" means [***];

"Major EU Market" means [***].

"Milestone Event" means the relevant event as set out in column 1 of Part B of
this Schedule 5, which shall trigger the relevant Milestone Payment. In
addition:

| 
---|--- 

a)

|

where [***], it shall be considered a "Milestone Event" in respect of which
the Buyer will pay to the Sellers a one-time payment (which shall constitute a
"Milestone Payment") of [***]; 

| 
---|--- 

b)

|

[intentionally left blank]; 

| 
---|--- 

c)

|

[intentionally left blank]; and 

| 
---|--- 

d)

|

[***]; 

 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|


"Milestone Payment" means, with respect to a Milestone Event:

| 
---|--- 

a)

|

if [***], a payment equal to [***] of the "Maximum Milestone Payment" amount
set out column 2 of Part B of this Schedule 5 in the row corresponding to the
applicable Milestone Event; and 

| 
---|--- 

b)

|

if [***], a payment equal to [***] of the "Maximum Milestone Payment" amount
set out column 2 of Part B of this Schedule 5 in the row corresponding to the
applicable Milestone Event; 

In no event will more than one Milestone Payment be made for a given Milestone
Event, regardless of how many mAb2 Products achieve such Milestone Event,
except that [***], then a second Milestone Payment shall become due with
respect to such Milestone Event, in an amount equal to [***] of the "Maximum
Milestone Payment" amount set out column 2 of Part B of this Schedule 5 in the
row corresponding to the applicable Milestone Event. For clarity, under no
circumstances will the total Milestone Payments that the Buyer becomes
obligated to make in respect to a given Milestone Event exceed the "Maximum
Milestone Payment" amount set out column 2 of Part B of this Schedule 5 in the
row corresponding to the applicable Milestone Event;

"Net Sales" means, with respect to a mAb2 Product for any period, the total
amount billed or invoices on sales of such mAb2 Product during such period by
the Buyer, its Affiliates or sublicensees, calculated in accordance with the
definition of "Net Sales" used in the License Agreement, and reading all
references to Licensed Products in such definition as references to mAb2
Products;

"Non-conforming mAb2" means a mAb2 Product that is not a Conforming mAb2;

"Payment Date" means the date which is 90 calendar days after any date on
which a Milestone Payment is triggered;

"Regulatory Approval" has the meaning given to it in the License Agreement;

"Relevant Period" means the period from Completion until [***];

"Remaining Amount" means the aggregate Contingent Consideration payable
pursuant to [***] minus the aggregate Contingent Consideration actually paid
by the Buyer pursuant to [***] prior to the date of delivery of a Default
Notice;

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|


"Risk-Adjusted Remaining Amount" means [***];

"Total Contingent Consideration" means the aggregate of the Milestone
Payments; and

"US Regulatory Milestone" means [***].

| 
---|--- 

2.

|

Conduct of business during Relevant Period 

Commercially Reasonable Efforts

| 
---|--- 

2.1.

|

The Buyer shall during the Relevant Period use Commercially Reasonable Efforts
to achieve both of the EU Regulatory Milestone and the US Regulatory
Milestone. The Sellers acknowledge and agree that, in addition to the
foregoing: 

| 
---|--- 

(a)

|

the Buyer shall be deemed to have satisfied its obligations under this
paragraph 2.1 of Schedule 5 so long as the Buyer is using Commercially
Reasonable Efforts to advance [***] toward achievement of the [***]; 

| 
---|--- 

(b)

|

the Buyer shall have the right to satisfy its diligence obligations under this
paragraph 2.1 of Schedule 5 through its Affiliates or Sublicensees; and 

| 
---|--- 

(c)

|

nothing in this paragraph 2.1 of Schedule 5 is intended, or shall be
construed, to require the Buyer to Develop: 

| 
---|--- 

(i)

|

[***]; or 

| 
---|--- 

(ii)

|

[***] 

| 
---|--- 

2.2.

|

If at any time the Sellers have a reasonable basis to believe that the Buyer
is in material breach of its obligations under paragraph 2.1 of Schedule 5 and
such material breach has continued for a period of at least [***] (a
"Continuing Material Breach"), then the Sellers shall cause the Sellers'
Representative to deliver written notice (the "Default Notice") of such
Continuing Material Breach to the Buyer and, if the Buyer fails to remedy such
Continuing Material Breach within 60 days of receipt of the Default Notice,
then the provisions of paragraph 2.3 shall apply. 

 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.




 

--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

2.3.

|

If the Buyer is in Continuing Material Breach of its obligations under
paragraph 2.1 and following receipt of a Default Notice fails to remedy such
Continuing Material Breach within the time period set out in paragraph 2.2,
then the Sellers' Representative may, by written notice to the Buyer, elect to
initiate an ADR proceeding pursuant to the procedures set forth in clause
23.3, and the arbitrators for such ADR proceeding shall be instructed and
required to conduct a proceeding for the sole purposes of [***]. In the event
[***] the Buyer is in Continuing Material Breach of its obligations under
paragraph 2.1, the Buyer shall pay to the Sellers [***] the Risk-Adjusted
Remaining Amount. 

| 
---|--- 

2.4.

|

Any amount to be paid by the Buyer pursuant to paragraph 2.3: 

| 
---|--- 

(a)

|

to the Cash Sellers, shall be paid by transfer of the relevant funds for same
day value to the Payments Administrator, 

| 
---|--- 

(b)

|

to the Loan Note Sellers, shall be paid by the issue by the Buyer of
Contingent Consideration Loan Notes to each of the Loan Note Sellers equal, in
principal amount, to the relevant amount due to each of them pursuant to
paragraph 2.3, 

in each case shall be made within 30 Business Days of the expiry of the time
period set out in paragraph 2.2 without set off, deduction or withholding
(except as required by law or by this Agreement).

| 
---|--- 

2.5.

|

The Sellers agree between themselves that any payments to the Payments
Administrator pursuant to paragraph 2.4 shall be apportioned, and the
principal amount of any Contingent Consideration Loan Notes issued pursuant to
paragraph 2.4 shall be calculated, by reference to the Sellers' respective
Proportion of Initial Consideration. The Buyer shall not be responsible for
how any such payment to the Payments Administrator is allocated or applied by
the Payments Administrator. 

| 
---|--- 

2.6.

|

A payment or issue of Contingent Consideration Loan Notes by the Buyer
pursuant to paragraph 2.3 shall not discharge the Buyer of its obligation to
pay any further Contingent Consideration (if any) above the amounts paid to
the Sellers in accordance with paragraph 2.3 upon achievement of the relevant
Milestone Events. 

| 
---|--- 

2.7.

|

The parties acknowledge that: 

| 
---|--- 

(a)

|

any provision in this Agreement that imposes a detriment on a party in breach,
in particular as set out in paragraph 2.3 of this Part A of Schedule 5,
represents a genuine pre-estimate of the loss expected to be suffered by the
party not in breach, and: 

 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

(i)

|

protects the legitimate interests of the other parties in the enforcement of
the obligation breached; and 

| 
---|--- 

(ii)

|

is not out of all proportion to those legitimate interests; and 

| 
---|--- 

(b)

|

they are of comparable bargaining power and each of them has been properly
advised in relation to this Agreement. 

Record Keeping and Reporting

| 
---|--- 

2.8.

|

The Buyer agrees that during the period whilst further Contingent
Consideration is payable in accordance with this Schedule 5 it shall, and
shall procure that each other Buyer's Group Undertaking shall: 

| 
---|--- 

(a)

|

prepare and maintain reasonably complete and accurate records regarding any
Commercialisation or Development efforts which relate to any mAb2 Product and
all other data necessary for the calculation of the Contingent Consideration; 

| 
---|--- 

(b)

|

once per calendar year, on 31 January, and subject to reasonable procedures
and agreements to preserve confidentiality, provide the Sellers'
Representative with a written report on material developments with respect to
the Development and Commercialisation of any mAb2 Product, together with such
reasonable additional information regarding any such activities or events as
the Sellers' Representative may reasonably request from time to time (subject
to any applicable third party confidentiality restrictions) which shall
include copies of relevant documents as requested by the Sellers'
Representative; and 

| 
---|--- 

(c)

|

once per calendar year during the Relevant Period, within 30 days of the
Sellers' Representative's written request, meet in person or by telephone with
the Sellers' Representative. At such meetings, the Buyer shall cause senior
officers from the research, clinical development, and business operations of
the Buyer and/or the Buyer's Group Undertakings to attend, to present and to
answer questions. Each of the Buyer and the Sellers' Representative (on behalf
of the Sellers) shall bear its own costs and expenses regarding such meetings. 

| 
---|--- 

2.9.

|

Upon receipt of a request from the Sellers' Representative, the Buyer shall,
and shall ensure each of Buyer's Group Undertakings shall, permit an
independent auditor designated by the Sellers' Representative to inspect and
audit the records and books of account maintained by it pursuant to paragraph
2.8 in order to confirm the accuracy and completeness of such records and
books of account and the calculation of the Contingent Consideration. Any such
audit shall (i) be for a reasonable duration during office hours on a Business
Day; (ii) be upon notice of at least 30 days; and (iii) not be requested more
than once during each 

 

 
--- 
| | 

CONFIDENTIAL

|


financial year of the period during which any Contingent Consideration remains
payable. The Sellers' Representative (on behalf of the Sellers) shall pay the
costs of each audit unless the audit reveals a variance of more than [***]
between the amounts paid and the amounts due, in which case the Buyer shall
bear the cost of the audit, provided, however, that in the event the audit
pertains to achievement of a Milestone Event relating to the Buyer's Net
Sales, the Sellers' Representative (on behalf of the Sellers) shall pay the
costs of each audit unless the audit reveals a variance of more than [***]
between the Net Sales reported by Buyer and the Net Sales determined by the
audit. If the audit reveals an underpayment by the Buyer, the Buyer shall
transfer the amount by which it had underpaid by transfer of funds for same
day value to the Payments Administrator for further distribution to the
Sellers within 10 Business Days after the date on which such audit is
completed.





*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|




Part B: Milestone Payment Amounts 

--- 
| 

Column 1: Milestone Event

|

Column 2: Maximum Milestone Payment (US$) 

[***]

|

[***] 

[***]

|

[***] 

[***]

|

[***] 

[***]

|

[***] 

[***]

|

[***] 

[***]

|

[***] 

[***]

|

[***] 

TOTAL =

|

[***] 

* The maximum Milestone Payment for this Milestone Event shall be increased by [***]. 





*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.




 

--- 
| | 

CONFIDENTIAL

|




SCHEDULE 6

[***]

Part A: [***]

| 
---|--- 

1.

|

CAPACITY AND AUTHORITY 

| 
---|--- 

1.1.

|

The Seller has the right, power and authority to execute, deliver and perform
its obligations under this Agreement and any other Transactional Document to
be executed by the Seller and, where the Seller is not an individual, all such
obligations of the Seller have been duly and validly approved and authorized
by all necessary action on the part of such Seller, and no other action on the
part of such Seller is required in connection therewith. 

| 
---|--- 

1.2.

|

If such Seller is not an individual, it has been duly incorporated and is
validly existing and in good standing under the laws of the jurisdiction in
which it is incorporated or constituted (to the extent that such concepts are
recognised in such jurisdiction). 

| 
---|--- 

1.3.

|

The Seller's obligations under this Agreement and any other Transactional
Document to be executed by the Seller are, or when the relevant document is
executed will be, enforceable in accordance with their terms, subject to the
effects of bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other similar laws relating to or affecting creditors' rights
generally and general equitable principles 

| 
---|--- 

1.4.

|

The execution and delivery of, and the performance by the Seller of its
obligations under, this Agreement and any of the Transactional Documents will
not: 

| 
---|--- 

(a)

|

if relevant, result in a breach of any provision of its articles of
association or by-laws; 

| 
---|--- 

(b)

|

result in a breach of, or constitute a default under, any instrument to which
the Seller is a party or by which the Seller is bound where such breach may
prejudice the transactions contemplated by this Agreement or any of the
Transaction Documents; or 

| 
---|--- 

(c)

|

result in a breach of any order, judgment or decree of any court or Authority
to which the Seller is a party or by which the Seller is bound or submits
where such breach may prejudice the transactions contemplated by this
Agreement or any of the Transaction Documents. 

 






 

--- 
| | 

CONFIDENTIAL

|


*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.

| 
---|--- 

2.

|

SHARES 

| 
---|--- 

2.1.

|

The Seller's Relevant Shares constitute the whole of the Seller's interest in
the allotted and issued share capital of the Company and the Seller does not
exercise voting power over any other outstanding shares or other equity
interests of the Company. 

| 
---|--- 

2.2.

|

The Seller is entitled to sell and transfer or procure the transfer of the
full legal and beneficial ownership of its Relevant Shares to the Buyer on the
terms set out in this Agreement. 

| 
---|--- 

2.3.

|

The Shares registered in the name of the Seller and set out opposite his name
at columns B and C (as applicable) of Schedule 1 have been properly allotted
and issued and are fully paid and such Shares will be sold free of all
Encumbrances and there is no agreement, arrangement or obligation to give or
create any such Encumbrance. No person has claimed to be entitled to an
Encumbrance in relation to any such Shares. 

 

 
--- 
| | 

CONFIDENTIAL

|




Part B: [***]

| 
---|--- 

1.

|

SHARES 

| 
---|--- 

1.1.

|

At Completion, the Shares are registered in the name of the Sellers and set
out opposite their names at columns B and C (as applicable) of Schedule 1 and
constitute the entire issued share capital of the Company, have been properly
allotted and issued and are fully paid or credited as fully paid. 

| 
---|--- 

1.2.

|

Other than this Agreement, the Transaction Documents, the Shareholders'
Agreement or as referred to or contemplated by this Agreement, there is no
agreement, arrangement or obligation requiring the creation, allotment, issue,
transfer, redemption or repayment of, or the grant to a person by the Company
of the right (conditional or not) to require the allotment, issue, transfer,
redemption or repayment of, a share in the capital of the Company (including
an option or right of pre emption or conversion). 

| 
---|--- 

1.3.

|

So far as the Warrantors are aware, no person has claimed to be entitled to an
Encumbrance in relation to any Shares. 

| 
---|--- 

1.4.

|

Save for this Agreement, the Transaction Documents, the Company's articles of
association and the Shareholders' Agreement, there are no contracts relating
to voting, purchase, sale or transfer of any Shares (i) between or among the
Company and any Shareholder, and (ii) so far as the Warrantors are aware,
between or among any of the Shareholders. 

| 
---|--- 

2.

|

THE GROUP 

| 
---|--- 

2.1.

|

The Company does not have, and has not at any time had, any subsidiary
undertakings. 

| 
---|--- 

2.2.

|

Other than as contemplated by this Agreement, the Company has no interest in,
and has not agreed to acquire an interest in or merge or consolidate with, a
corporate body or any other person. 

| 
---|--- 

2.3.

|

The information contained in Schedule 1 (The Sellers) and Schedule 2
(Information about the Company) is true and accurate. 

 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.




 

--- 
| | 

CONFIDENTIAL

|


SCHEDULE 7

[***]

| 
---|--- 

1.

|

ORGANIZATION 

| 
---|--- 

1.1

|

The Company is a company duly incorporated and validly existing under the laws
of England and Wales and has the right, power and authority to execute,
deliver and perform its obligations under this Agreement and any other
Transactional Document to be executed by it. 

| 
---|--- 

1.2

|

The Company's obligations under this Agreement and any other Transactional
Documents to be executed by the Company are, or when the relevant document is
executed will be, enforceable in accordance with their terms, subject to the
effects of bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other similar laws relating to or affecting creditors' rights
generally and general equitable principles. 

| 
---|--- 

2.

|

ACCOUNTS 

| 
---|--- 

2.1

|

General 

| 
---|--- 

2.1.1

|

The Accounts have been prepared and audited on a proper and consistent basis
in accordance with the law and applicable standards, principles and practices
generally accepted in the United Kingdom. 

| 
---|--- 

2.1.2

|

The Accounts show a true and fair view of the state of affairs of the Company
as at the Last Accounting Date and of the profit or loss of the Company for
the financial year ended on the Last Accounting Date. 

| 
---|--- 

2.1.3

|

Save as disclosed in the Accounts, the Accounts have been prepared using the
same accounting policies as those adopted and applied in preparing the
accounts for the previous two years. 

| 
---|--- 

2.1.4

|

The Company does not have any liabilities of any nature other than (i) those
set forth or adequately provided for in the Accounts, (ii) those incurred in
the conduct of the Company's business since the Last Accounting Date in the
ordinary course, and which, individually or in the aggregate, are not material
in nature or amount and do not result from any breach by the Company of any
contract, warranty, infringement, tort or violation of law to which it is
subject, and (iii) those incurred by the Company in connection with the
execution of this Agreement. Except for liabilities reflected in the Accounts,
the Company has no off balance sheet liability of any nature to, or any
material financial interest in, any third party or entities, the purpose or
effect of which is to defer, postpone, reduce or otherwise avoid or adjust the
recording of expenses incurred by the Company. Without limiting the generality
of the foregoing, the Company has never guaranteed any debt or other
obligation of any other person. 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

2.2

|

Provision for Tax 

The Accounts include provision or reserve (as appropriate) in accordance with
the relevant accounting standards for Tax liable to be assessed on the Company
or for which the Company is accountable in respect of profits earned, accrued
or received on or before the Last Accounting Date, and in respect of any event
occurring on or before the Last Accounting Date.

| 
---|--- 

2.3

|

Accounting records 

The Company's accounting records are up-to-date in all material respects, are
in its possession or under its control and are properly completed in
accordance with the law and applicable standards, principles and practices
generally accepted in the United Kingdom.

| 
---|--- 

3.

|

CHANGES SINCE THE LAST ACCOUNTING DATE 

| 
---|--- 

3.1

|

Since the Last Accounting Date: 

| 
---|--- 

3.1.1

|

the Company's business has in all material respects been operated in the usual
way so as to maintain it as a going concern; 

| 
---|--- 

3.1.2

|

there has been no material adverse change in the financial or trading position
of the Company or the properties, assets (including intangible assets),
liabilities, business, prospects, capitalization, employees, operations or
results of operations of the Company or any change that would reasonably be
expected to materially impede or delay the Company's ability to consummate the
transactions contemplated by this Agreement, other than any event,
circumstance or change resulting from changes in stock markets, interest
rates, exchange rates, commodity prices or other general economic conditions
or changes in conditions affecting the industry generally in which the Company
operates; 

| 
---|--- 

3.1.3

|

the Company has not made or entered into any contract or letter of intent with
respect to, or otherwise effected, any acquisition, sale, license, disposition
or transfer of any asset that is material to the business of the Company,
including without limitation, Intellectual Property other than IP Licenses
Out; 

| 
---|--- 

3.1.4

|

there has not occurred any change in accounting methods or practices
(including any change in depreciation or amortization policies or rates or
revenue recognition policies or establishment of reserves) by the Company or
any revaluation by the Company of any of its assets; 

| 
---|--- 

3.1.5

|

there has not occurred any declaration, setting aside, or payment of a
dividend or other distribution with respect to any securities of the Company,
or any redemption, purchase or other acquisition by the Company of any of its
securities, or any change in any rights, preferences, privileges or
restrictions of any of its outstanding securities; 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

3.1.6

|

the Company has not entered into, amended, renewed or terminated any Material
Contract (as hereinafter defined), and there has not occurred any material
default or breach under any Material Contract to which the Company is a party
or by which it is, or any of its assets and properties are, bound; 

| 
---|--- 

3.1.7

|

the Company has not incurred, created or assumed any Encumbrance on any of its
assets or properties, any material indebtedness, or any liability as guarantor
or surety with respect to the obligations of any other person; and 

| 
---|--- 

3.1.8

|

the Company has not paid or discharged any Encumbrance or liability which was
not shown on the Accounts or incurred in the ordinary course of business
consistent with past practice since the Last Accounting Date. 

| 
---|--- 

4.

|

TAX 

| 
---|--- 

4.1

|

The Company has, within the last three years, where legally obliged to do so: 

| 
---|--- 

4.1.1

|

duly and punctually paid all Tax which it has become liable to pay, whether or
not shown or required to be shown on any Tax return; 

| 
---|--- 

4.1.2

|

duly deducted, withheld or collected for payment (as appropriate) all Tax due
to have been deducted, withheld or collected for payment and has accounted for
or paid all such Tax to the relevant Tax Authority (to the extent due); and 

| 
---|--- 

4.1.3

|

not been liable to pay any material interest, penalty or surcharge in respect
of any unpaid Tax. 

| 
---|--- 

4.2

|

All returns, computations, information, accounts and notices which are or have
been required by law to be made or given by the Company within the last three
years for any Tax purposes have been made or given in the required form and
have been properly submitted by the Company and are complete and accurate in
all material respects. 

| 
---|--- 

4.3

|

The Company has, in the last three years, in all material respects, complied
at all times with all statutory requirements, regulations, notices, orders,
directions and conditions relating to all relevant Taxes, including the terms
of any agreement made with HMRC or any other relevant Tax Authority. 

| 
---|--- 

4.4

|

The Company is not, nor has it at any time within the last three years, been
involved in any dispute with or non-routine investigation, audit or discovery
by any Tax Authority and, so far as the Warrantors are aware, no such dispute,
investigation, audit or discovery is planned. 

| 
---|--- 

4.5

|

There are no liens or encumbrances against any of the Company's assets,
arising in connection with a failure to pay any Tax. 

| 
---|--- 

4.6

|

In the last three years, each related party transaction involving the Company
is and has been at arm\'s-length in all material respects and determined in
compliance in all material respects with applicable transfer pricing rules and
regulations. 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

4.7

|

The Company does not have any outstanding waivers or extension of the statute
of limitations for assessment of any Tax. 

| 
---|--- 

4.8

|

The Company is not a party to, or bound by, any Tax indemnity agreement, Tax
sharing agreement or Tax allocation agreement with respect to Taxes (other
than any agreement entered into in the ordinary course of business and not
primarily related to Taxes) and other than this Agreement, the Spin-Out
License, and the License Agreement and any other agreement contemplated by any
such agreements. The Company is not liable for Taxes of any other Person (i)
under any applicable Law, (ii) as a transferee of any assets or successor to
any liabilities, or (iii) by Contract, indemnity or otherwise, including by
reason of the transactions contemplated by the Gamma IP License. 

| 
---|--- 

4.9

|

In the last three years, no written claim has been made by any Tax Authority
in a jurisdiction where the Company does not file Tax Returns that the Company
is or may be subject to Taxation by that jurisdiction. 

| 
---|--- 

4.10

|

The Company will not, after the Completion Date, be liable under any
applicable Law, by Contract, indemnity or otherwise as a transferee of any
assets or successor to any liabilities, for any Taxes of F-star, F-star GmbH,
or any of their Affiliates as a result of (i) the Company's entry into, and
transactions contemplated by, the Gamma IP License, the License Agreement and
the Services Agreement and/or (ii) the transactions contemplated by the Option
Agreement and this Agreement other than VAT as provided for in any agreement. 

| 
---|--- 

5.

|

ASSETS 

| 
---|--- 

5.1

|

Title and condition 

| 
---|--- 

5.1.1

|

Each asset included in the Accounts or acquired by the Company since the Last
Accounting Date is: 

| 
---|--- 

(a)

|

legally and beneficially owned solely by the Company; 

| 
---|--- 

(b)

|

where capable of possession, in the possession or under the control of the
Company. 

| 
---|--- 

5.1.2

|

Company owns or has the right to use each asset used in and necessary for the
effective operation of its business. 

| 
---|--- 

6.

|

INTELLECTUAL PROPERTY 

The Company owns, or has rights to use, all Intellectual Property materially
necessary for the Company to operate its business.

| 
---|--- 

6.1

|

Registered Owned IP 

| 
---|--- 

6.1.1

|

The Disclosure Letter sets out details of all material registered Intellectual
Property owned by the Company ("Registered Owned IP"). The Company solely owns
the Registered Owned IP. 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

6.1.2

|

To the best of the knowledge, information and belief of the Warrantors, (i)
there are no issued patents or registered trademarks within the Registered
Owned IP that are invalid or unenforceable and (ii) there are no patent
applications included within the Registered Owned IP that have not been duly
filed and diligently prosecuted. 

| 
---|--- 

6.1.3

|

The Company has received an assignment of rights from each inventor listed in
the patents and patent applications included in the Disclosure Letter save in
the case of those inventors which are employees of the Company and whose
inventions vest in the Company by virtue of their employment relationship. The
Company is the sole legal and beneficial owner of each of the patents and
patent applications. 

| 
---|--- 

6.1.4

|

All issuance, renewal and maintenance fees due up to and including the date of
this Agreement in respect of each of the Registered Owned IP have been paid in
full and on time. 

| 
---|--- 

6.2

|

No infringement by Company of third party Intellectual Property 

| 
---|--- 

6.2.1

|

To the best of the knowledge, information and belief of the Warrantors, the
activities of the Company, and the practice of the inventions claimed under
the Registered Owned IP, do not nor have they in the year prior to the date of
this Agreement infringed, misappropriated, misused, violated or otherwise made
use without authorisation of any third party Intellectual Property nor has any
person threatened to the Company in writing to issue such a notice. 

| 
---|--- 

6.2.2

|

To the best of the knowledge, information and belief of the Warrantors, the
Company has not issued any opposition, invalidation, revocation or
cancellation proceeding or any other proceeding or counterclaim (including any
litigation, arbitration or proceeding pursuant to any other dispute resolution
mechanism) concerning the validity, enforceability or title to any
Intellectual Property of any third party. 

| 
---|--- 

6.3

|

IP Licenses In and IP Licenses Out 

| 
---|--- 

6.3.1

|

Copies of all material licenses of Intellectual Property granted by the
Company ("IP Licenses Out") and granted to the Company ("IP Licenses In") are
included in the Disclosure Bundle. 

| 
---|--- 

6.3.2

|

To the best of the knowledge, information and belief of the Warrantors, no IP
License In or IP License Out is currently being, or has at any time been,
breached in a material way by the Company or to the best of the Warrantors'
knowledge, information and belief, by any other party thereto. So far as the
Warrantors are aware, the rights granted under the IP Licenses In and IP
Licenses Out will not be adversely affected by the transactions contemplated
by this Agreement. 

| 
---|--- 

6.3.3

|

To the best of the knowledge, information and belief of the Warrantors, all
fees, royalties or other amounts due to be paid by or to the Company in
respect of any IP License In or IP License Out have been paid in a timely
manner and no such payments have been outstanding for more than 60 days. 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

6.4

|

Company Confidential Information 

| 
---|--- 

6.4.1

|

To the best of the knowledge, information and belief of the Warrantors, all
Company Confidential Information held by the Company is accurately and
properly documented to enable the Buyer to acquire and retain its full benefit
and is subject to appropriate storage and security measures to preserve the
confidentiality and secrecy of such Company Confidential Information. 

| 
---|--- 

6.4.2

|

To the best of the knowledge, information and belief of the Warrantors, the
Company has not disclosed any Company Confidential Information to any person
other than (i) its employees and advisors who are bound by obligations of
confidence (howsoever arising); (ii) in circumstances where such disclosures
have been made in the ordinary course of business; and (iii) pursuant to the
IP Licenses Out and the IP Licenses In. 

| 
---|--- 

7.

|

INSURANCE 

| 
---|--- 

7.1

|

Policies 

The Disclosure Letter sets out a list of insurance policies maintained by or
on behalf of the Company (together the "Policies");

| 
---|--- 

7.2

|

Status of the Policies 

Each of the Policies is valid and enforceable and the Warrantors are not aware
of any circumstances that would render any of them void or voidable.

| 
---|--- 

7.3

|

Premiums 

All premiums which are due under the Policies have been paid.

| 
---|--- 

8.

|

MATERIAL CONTRACTS 

| 
---|--- 

8.1

|

Validity of Material Contract 

| 
---|--- 

8.1.1

|

Save for the Transaction Documents. the Company is not a party to or bound by
any of the following contracts (each a "Material Contract"): 

| 
---|--- 

(a)

|

any contract limiting the freedom of the Company to engage or participate, or
compete with any other person, in any line of business, market or geographic
area, or to make use of any Intellectual Property, or any contract granting
exclusive rights, rights of refusal, rights of first negotiation or similar
rights and/or terms to any person, or any contract otherwise limiting the
right of the Company to sell, distribute or manufacture any products or
services or to purchase or otherwise obtain any products or services; 

| 
---|--- 

(b)

|

any licenses, sublicenses and other contracts pursuant to which any person is
granted any rights to Intellectual Property of the Company or pursuant to
which the Company has agreed to any restriction on the right of the Company 

 

 
--- 
| | 

CONFIDENTIAL

|


to use or enforce any Intellectual Property owned by the Company or pursuant
to which the Company agrees to encumber, transfer or sell rights in or with
respect to any Intellectual Property owned by the Company; or

| 
---|--- 

(c)

|

any other contract or obligation that individually had or has a value or
payment obligation in excess of US$50,000 over the life of the contract or is
otherwise material to the Company or its businesses, operations, financial
condition, properties or assets. 

| 
---|--- 

8.1.2

|

Each of the Material Contracts is in full force and effect, subject only to
the effect, if any, of applicable bankruptcy and other similar laws affecting
the rights of creditors generally and rules of law governing specific
performance, injunctive relief and other equitable remedies. 

| 
---|--- 

8.1.3

|

No party to a Material Contract has given notice of its intention to terminate
to the Company, or has sought to repudiate or disclaim, the Material Contract. 

| 
---|--- 

8.1.4

|

Neither the Company nor, so far as the Warrantors are aware, any party with
whom the Company has entered into a Material Contract is in material breach of
the Material Contract. 

| 
---|--- 

8.1.5

|

So far as the Warrantors are aware, no circumstances exist which would give
rise to any breach of any Material Contract or to any such Material Contract
being terminated or varied without the Company's consent (other than
termination without cause upon notice in accordance with the terms of the
agreement). 

| 
---|--- 

9.

|

EFFECT OF SALE 

Neither the execution nor the performance of this Agreement or any document to
be executed at or before the Completion Date will result in the Company losing
the benefit of any material asset, grant, subsidy, right or privilege which it
enjoys at the date of this Agreement.

| 
---|--- 

10.

|

LIABILITIES 

| 
---|--- 

10.1

|

Indebtedness 

The Company does not have outstanding and has not agreed to create or incur
loan capital, borrowings, indebtedness in the nature of borrowings other than
the trade debt incurred in the ordinary and usual course of trading.

| 
---|--- 

10.2

|

Guarantees and indemnities 

The Company is not a party to and is not liable under a guarantee, indemnity
or other agreement to secure or incur a financial or other obligation with
respect to another person's obligation.

| 
---|--- 

10.3

|

Grants 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

10.3.1

|

The Company is not liable to repay an investment or other grant or subsidy
made to it by a body (including the Department for Business, Innovation and
Skills or its predecessor). 

| 
---|--- 

10.3.2

|

No fact or circumstance (including the execution and performance of this
Agreement) exists which might entitle a body to require repayment of, or
refuse an application by the Company for, the whole or part of a grant or
subsidy. 

| 
---|--- 

11.

|

RESTRICTIONS ON BUSINESS ACTIVITIES 

Other than the Transaction Documents, there is no contract, judgment,
injunction, order or decree binding upon the Company as of the date of this
Agreement which has or would reasonably be expected to have, whether before or
after Completion, the effect of prohibiting, restricting or impairing any
current or presently proposed business practice of the Company, any
acquisition of property by the Company or the conduct or operation of the
Company's business or limiting the freedom of the Company to engage in any
line of business, to sell, license or otherwise distribute services or
products in any market or geographic area, or to compete with any person.

| 
---|--- 

12.

|

SERVICE PROVIDERS 

| 
---|--- 

12.1

|

The Company has never employed or engaged any employees, consultants, advisory
board members, or independent contractors. The Company has never maintained or
offered any: 

| 
---|--- 

12.1.1

|

employee benefit plans; 

| 
---|--- 

12.1.2

|

loan to any independent contractor or consultant; 

| 
---|--- 

12.1.3

|

stock option, stock purchase, phantom stock, stock appreciation right,
supplemental retirement, severance, sabbatical, medical, dental, vision care,
disability, employee relocation, cafeteria benefit, dependent care, life
insurance or accident insurance plans, programs or arrangements; 

| 
---|--- 

12.1.4

|

bonus, pension, profit sharing, savings, severance, retirement, deferred
compensation or incentive plans, programs or arrangements; 

| 
---|--- 

12.1.5

|

other fringe or employee benefit plans, programs or arrangements; or 

| 
---|--- 

12.1.6

|

employment or executive compensation or severance agreements, written or
otherwise. 

| 
---|--- 

12.2

|

None of the execution and delivery of this Agreement, the Completion or any
other transaction contemplated hereby or any termination of employment or
service or any other event in connection therewith or subsequent thereto will,
individually or together or with the occurrence of some other event: 

| 
---|--- 

12.2.1

|

result in any payment (including severance, unemployment compensation, golden
parachute, bonus or otherwise) becoming due to any person; 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

12.2.2

|

increase or otherwise enhance any benefits otherwise payable by the Company; 

| 
---|--- 

12.2.3

|

result in the acceleration of the time of payment or vesting of any such
benefits; 

| 
---|--- 

12.2.4

|

obligate the payment of compensation to any person; or 

| 
---|--- 

12.2.5

|

result in the forgiveness in whole or in part of any outstanding loans made by
the Company to any person. 

| 
---|--- 

13.

|

INTERESTED PARTY TRANSACTIONS 

None of the officers and directors of the Company and, as far as the
Warrantors are aware, none of the employees of the Company or Shareholders,
nor, so far as the Warrantors are aware, any immediate family member of an
officer, director, employee or Shareholder, has any direct or indirect
ownership, participation, or other interest in, or is an officer, director,
employee of or consultant or contractor for any firm, partnership, entity or
corporation that competes with, or does business with, or has any contractual
arrangement with, the Company (except with respect to (i) F-star or F-star
GmbH or (ii) any interest in less than five per cent (5%) of the issued share
capital of any Company whose shares are publicly traded). None of said
officers, directors or Shareholders or, so far as the Warrantors are aware,
any employees or member of their immediate families of the foregoing, is a
party to or otherwise directly interested in, any contract to which the
Company is a party or by which the Company or any of its assets or properties
may be bound or affected in a material manner. As far as the Warrantors are
aware, none of said officers, directors, employees or Shareholders has any
material interest in any property, real or personal, tangible or intangible
(including any Intellectual Property) that is directly related to the business
of the Company.

| 
---|--- 

14.

|

COMPLIANCE WITH OPTION AGREEMENT 

At all times since the Effective Date (as defined in the Option Agreement) the
Company has complied in all material respects with its covenants set forth in
the Option Agreement.

| 
---|--- 

15.

|

INSOLVENCY, WINDING UP ETC. 

| 
---|--- 

15.1

|

Winding up 

No order has been made, petition presented or resolution passed for the
winding up of the Company or for the appointment of a liquidator or
provisional liquidator to the Company.

| 
---|--- 

15.2

|

Administration 

No administrator has been appointed in relation to the Company. So far as the
Warrantors are aware, no notice has been given or filed with the court of an
intention to appoint an administrator. No petition or application has been
presented or order made for the appointment of an administrator in respect of
the Company.

| 
---|--- 

15.3

|

Receivership 

 

 
--- 
| | 

CONFIDENTIAL

|


No receiver or administrative receiver has been appointed, nor any notice
given of the appointment of any such person, over the whole or part of the
Company's business or assets.

| 
---|--- 

15.4

|

Moratorium 

No moratorium has been sought or has been granted under section 1A of the
Insolvency Act 1986 in respect of the Company.

| 
---|--- 

15.5

|

Voluntary arrangements 

No voluntary arrangement has been proposed under section 1 of the Insolvency
Act 1986 in respect of the Company.

| 
---|--- 

15.6

|

Scheme of arrangement 

No compromise or arrangement has been proposed, agreed to or sanctioned under
Part 26 (Arrangements and Reconstructions) of the Act in respect of the
Company, nor has any application been made to, or filed with, the court for
permission to convene a meeting to vote on a proposal for any such compromise
or arrangement.

| 
---|--- 

15.7

|

Informal arrangements with creditors 

The Company has not proposed or agreed to a composition, compromise,
assignment or arrangement with any of its creditors.

| 
---|--- 

15.8

|

Inability to pay debts 

The Company is not unable to pay its debts within the meaning of section 123
of the Insolvency Act 1986. There are no unsatisfied written demands that have
been served on the Company pursuant to section 123(1)(a) of the Insolvency Act
1986. There is no unsatisfied judgment or court order outstanding against the
Company.

| 
---|--- 

15.9

|

Payment of debts 

The Company has not stopped payment of, nor is it unable to pay, its debts as
they fall due, nor has the Company commenced negotiations with one or more of
its creditors with a view to rescheduling or restructuring any of its
indebtedness.

| 
---|--- 

15.10

|

Distress 

No distress, execution, attachment, sequestration or other process has been
levied on an asset of the Company which remains undischarged.

| 
---|--- 

15.11

|

Striking out 

No action is being taken by the Registrar of Companies to strike the Company
off the register under section 1000 of the Act.

| 
---|--- 

15.12

|

Analogous proceedings 

 

 
--- 
| | 

CONFIDENTIAL

|


The Company is not, in any jurisdiction, subject to or threatened by any other
procedures or steps which are analogous to those set out above.

| 
---|--- 

16.

|

COMPETITION 

So far as the Warrantors are aware, the Company has not failed to comply with
or infringed the competition laws or regulations of any jurisdiction or been
investigated for alleged non-compliance or infringement or given any
undertaking in connection therewith.

| 
---|--- 

17.

|

LITIGATION AND COMPLIANCE WITH LAW 

Nothing in this Warranty concerns any matters concerned with any Intellectual
Property.

For the purposes of this paragraph 12:

"Agent" means, with respect to an entity, any director, officer, employee or
other representative of such entity; any person for whose acts such entity may
be vicariously liable; and any other person that acts for or on behalf of, or
provides services for or on behalf of, such entity, in each case, whilst
acting in his capacity as such;

| 
---|--- 

17.1

|

Litigation 

| 
---|--- 

17.1.1

|

Neither the Company nor, so far as the Warrantors are aware, a person for
whose acts or defaults the Company may be vicariously liable is involved, or
has been involved, in a civil, criminal, arbitration, administrative or other
proceeding. The Company has not received written notice that any civil,
criminal, arbitration, administrative or other proceeding is pending or
threatened by or against the Company or the assets or properties of the
Company, or any of the directors, officers or employees of the Company (in
their capacities as such or relating to their employment, services or
relationship with the Company) or, so far as the Warrantors are aware, a
person for whose acts or defaults the Company may be vicariously liable. So
far as the Warrantors are aware, there is no reasonable basis for any action,
suit, proceeding, claim, mediation, arbitration or investigation against the
Company or the assets or properties of the Company, or any of the directors,
officers or employees of the Company (in their capacities as such or relating
to their employment, services or relationship with the Company) or a person
for whose acts or defaults the Company may be vicariously liable. 

| 
---|--- 

17.1.2

|

There is no outstanding judgment, order, decree, arbitral award or decision of
a court, tribunal, arbitrator or governmental agency against the Company, any
of its assets or properties, or a person for whose acts or defaults the
Company may be vicariously liable. 

| 
---|--- 

17.1.3

|

So far as the Warrantors are aware, there is no reasonable basis for any
Person to asset a claim against the Company based upon the Company entering
into this Agreement or any of the Transaction Documents. 

 

 
--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

17.2

|

Compliance with law 

| 
---|--- 

17.2.1

|

The Company has conducted its business and dealt with its assets in all
material respects in accordance with applicable legal and administrative
requirements. 

| 
---|--- 

17.2.2

|

The Company has obtained each governmental consent, license, permit, grant, or
other authorization of a governmental entity that is required for the
operation of the Company's business or the holding of its assets or properties
(all of the foregoing consents, licenses, permits, grants, and other
authorizations, collectively, the "Company Authorizations") and all of the
Company Authorizations are in full force and effect. The Company has not
received any notice or other communication from any governmental entity
regarding (i) any actual or possible violation of law or of any Company
Authorization or any failure to comply with any term or requirement of any
Company Authorization or (ii) any actual or possible revocation, withdrawal,
suspension, cancellation, termination or modification of any Company
Authorization. None of the Company Authorizations will be terminated or
impaired, or will become terminable, in whole or in part, as a result of the
consummation of the transactions contemplated by this Agreement. 

| 
---|--- 

17.3

|

Investigations 

There is not and has not been any governmental or other investigation, enquiry
or disciplinary proceeding concerning the Company that the Company has been
notified of and, so far as the Warrantors are aware, none is pending or
threatened.

| 
---|--- 

17.4

|

Making unlawful payments 

Neither the Company nor, so far as the Warrantors are aware, any of its Agents
has paid, offered, promised, given or authorised the payment of money or
anything of value directly or indirectly to any person:

| 
---|--- 

17.4.1

|

intending to induce a person to improperly perform a function or activity or
to reward a person for any such performance; or 

| 
---|--- 

17.4.2

|

while knowing or believing that the acceptance by that person would constitute
the improper performance of a function or activity. 

| 
---|--- 

17.5

|

Receiving unlawful payments 

Neither the Company nor so far as the Warrantors are aware, have any of its
Agents has directly or indirectly requested, agreed to receive or accepted
money or anything of value:

| 
---|--- 

17.5.1

|

as a reward for the improper performance of a function or activity by any
person; 

| 
---|--- 

17.5.2

|

in circumstances which amount to an improper performance of a function or
activity; or 

| 
---|--- 

17.5.3

|

intending that as a consequence of any such request, agreement to receive or
acceptance a function or activity will be performed improperly. 

 

 
--- 
| | 

CONFIDENTIAL

|




SCHEDULE 8

Limitations on Sellers' Liability

| 
---|--- 

1.

|

LIMITATION ON QUANTUM 

| 
---|--- 

1.1.

|

No Warrantor shall be liable in respect of [***] unless and until the amount
that would otherwise be recoverable from the Warrantors (in aggregate) in
respect of [***], when aggregated with any other amounts recoverable in
respect of [***] exceeds [***] (the "Threshold"), in which case the Warrantors
shall be liable [***]. 

| 
---|--- 

1.2.

|

The total aggregate liability of the Warrantors in respect of [***] shall be
limited in accordance with clause 6.3. 

| 
---|--- 

1.3.

|

The liability in respect of each Seller in respect of [***] shall be limited
to a maximum amount equal to [***] of the aggregate of the Total Consideration
paid to such Seller, except for [***] with respect to [***] set forth in
[***], which shall be limited to a maximum amount of [***]. The liability in
respect of each Seller in respect of [***] shall be limited to a maximum
amount equal to [***], except in the case of [***], which shall be limited to
a maximum amount of [***]. 

| 
---|--- 

1.4.

|

The liability of each Seller, in respect of [***] made against such Seller,
and the liability of each Warrantor for [***] made against such Warrantor,
shall be limited to a maximum amount equal to [***]. 

| 
---|--- 

1.5.

|

Subject to paragraph 4 of this Schedule 8, the aggregate liability of any
Seller for all claims under this Agreement shall be limited to a maximum
amount equal to [***]. 

| 
---|--- 

2.

|

TIME LIMITATIONS 

| 
---|--- 

2.1.

|

No Seller, in respect of [***], or Warrantor, in respect of [***], shall be
liable for such Claim (as the case may be) unless the Buyer has given the
Sellers' Representative and each Warrantor notice of such Claim (as the case
may be), which notice shall state in reasonable detail the nature of the
Claim, the grounds on which it is based (including which Warranty has or
Warranties have been breached) and a good faith estimate of the amount claimed
and must be notified to the Sellers' Representative or Warrantor (as the case
may be): 

| 
---|--- 

(a)

|

on or before the date that is [***] after the Completion Date in respect of
[***]; 

 



*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

(b)

|

on or before [***] in respect of [***]; or 

| 
---|--- 

(c)

|

on or before [***] in respect of [***]. 

| 
---|--- 

2.2.

|

No Seller shall be liable for [***] or Warrantor shall be liable for [***]
unless proceedings in respect of such Claim (as the case may be) are issued
and served on the Sellers' Representative within a period of [***] starting on
the day of the Buyer's notification of such Claim pursuant to Section 2.1
above and provided that such Claim has not otherwise been satisfied, settled
or withdrawn. 

| 
---|--- 

3.

|

RECOURSE FOR [***] 

In the event that any Seller is liable to the Buyer in respect of [***]
following the earlier of (i) exhaustion of the money standing to the credit of
the Escrow Account and (ii) the Release Date, the Buyer's [***] recourse for
such liability shall be [***].

| 
---|--- 

4.

|

NO LIMITATION FOR FRAUD ETC. 

Nothing in this Schedule 8 shall have the effect of limiting or restricting
any liability of any Seller or Warrantor in respect of a Claim arising as a
result of any fraud, wilful misconduct or wilful concealment by or on behalf
of that Seller or Warrantor.

| 
---|--- 

5.

|

RECOVERY ONLY ONCE 

The Buyer is not entitled to recover more than once in respect of any one
matter giving rise to a loss or liability under this Agreement.

| 
---|--- 

6.

|

THIRD PARTY RECOVERY 

| 
---|--- 

6.1.

|

If the Sellers pay to a Buyer's Group Undertaking an amount in respect of a
Claim and a Buyer's Group Undertaking subsequently recovers from another
person an amount which is referable to the matter giving rise to the Claim: 

| 
---|--- 

(a)

|

if the amount paid by the Sellers in respect of the Claim is more than the Sum
Recovered, the Buyer shall promptly pay to the Sellers the Sum Recovered; and 

| 
---|--- 

(b)

|

if the amount paid by the Sellers in respect of the Claim is less than or
equal to the Sum Recovered, the Buyer shall promptly pay to the Sellers an
amount equal to the amount paid by the Sellers. 

 



*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|


For the purposes of paragraph 6.1 of this Schedule 8, "Sum Recovered" means an
amount equal to the total of the amount recovered from the other person plus
any interest in respect of the amount recovered from that person less all
reasonable costs incurred by a Buyer's Group Undertaking in recovering the
amount from the person.

| 
---|--- 

6.2.

|

If the Buyer or a Buyer's Group Undertaking becomes aware that matters have
arisen which will or could reasonably be expected to give rise to a Claim, the
Buyer will (or will procure that the relevant Buyer's Group Undertaking will)
where practicable (and provided such information is not subject to
confidentiality or is not privileged) disclose in writing to the Sellers'
Representative such information and documents relating to the Claim as the
Sellers' Representative may reasonably request (at the sole cost of the
Sellers) and will consult with those Sellers to the extent practicable and
have regard to their reasonable representations in respect of the resolution
of the Claim. 

| 
---|--- 

7.

|

ACCOUNTS 

The Sellers shall have no liability in respect of any Claim if and to the
extent that any allowance, provision or reserve was made or otherwise
reflected in the Accounts or the Completion Accounts in respect of the matter
or circumstances giving rise to the Claim.

| 
---|--- 

8.

|

TAX 

| 
---|--- 

8.1.

|

The Sellers shall not be liable in respect of [***] to the extent that: 

| 
---|--- 

(a)

|

it has been discharged or made good without cost or loss to the Buyer; or 

| 
---|--- 

(b)

|

it arises or is increased as a result of any increase in the rates of Tax
announced after the date of this Agreement; or 

| 
---|--- 

(c)

|

it arises or is increased by virtue of the failure or omission by the Company
or the Buyer to make any claim, election, surrender or disclaimer or give any
notice or consent or do any other thing after Completion (otherwise than at
the written request of the Sellers), the making, giving or doing of which was
taken into account or assumed in computing any provision or reserve for Tax in
the Completion Accounts; or 

| 
---|--- 

(d)

|

any Relief (other than a Relief which has been reflected or shown as an asset
in the Completion Accounts, or has been taken into account in calculating any
provisions for Tax in the Completion Accounts) is available to reduce or
eliminate such Tax liability. 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

9.

|

CHANGE IN LAW 

The Sellers shall not be liable in respect of any Claim to the extent that it
arises, or its value is increased, as a result of a change in any law,
legislation, rule or regulation (including any new law, legislation, rule or
regulation) that comes into force or otherwise takes effect after the date of
this Agreement.

| 
---|--- 

10.

|

VOLUNTARY ACTS 

| 
---|--- 

10.1.

|

The Sellers shall not be liable in respect of any Claim to the extent that the
matter or circumstance giving rise to such Claim arises, occurs or is
otherwise attributable to, or the Sellers' liability pursuant to such Claim is
increased as a result of: 

[***].

| 
---|--- 

10.2.

|

The Sellers shall not be liable in respect of any Claim to the extent that
[***]. 

| 
---|--- 

11.

|

SET OFF 

| 
---|--- 

11.1.

|

Subject to the procedures set forth in paragraph 11.2 below, the Buyer shall
be entitled to deduct from the Contingent Consideration payable to a Seller or
Sellers when it becomes due and payable in accordance with the provisions of
Schedule 5 (Contingent Consideration), an amount equal to any Claim which may
exist at the date upon which the Contingent Consideration falls due to be paid
by the Buyer; provided, however, that in respect of [***], the Buyer may only
deduct or withhold from the Contingent Consideration payable to the Sellers
the proportion of the Contingent Consideration (as notified by the Sellers'
Representative pursuant to clause 3.5 of the Agreement) that is due or becomes
due to [***]. 

 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.




 

--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

11.2.

|

If in connection with a payment of Contingent Consideration that has become
due and payable in accordance with the provisions of Schedule 5 (Contingent
Consideration), the Buyer in good faith believes that a Claim exists and the
Buyer intends to make a deduction to such Contingent Consideration as
permitted under paragraph 11.1 above, the Buyer shall, within three (3)
Business Days following such payment becoming due and payable, deliver to the
Sellers' Representative and each Warrantor a notice in writing (a "Set Off
Notice") of such Claim, which Set Off Notice shall state in reasonable detail
the nature of the Claim, the grounds on which it is based (including which
Warranty has or Warranties have been breached) and a good faith estimate of
the amount claimed (the "Set Off Claim"). If the Sellers' Representative
wishes to dispute the Set Off Claim on behalf of the Sellers or any Seller, it
may, within twenty (20) Business Days of receipt of the Set Off Notice,
indicate the same by written notice to the Buyer (the "Set Off Dispute
Notice") which also shall state in reasonable the basis for the Sellers'
Representative's dispute and the grounds on which it is based, in which case,
either the Buyer or the Sellers' Representative may then elect to initiate an
alternative dispute resolution proceeding pursuant to the procedures set forth
in clause 23.3 for purposes of having the Set Off Claim settled (a "Set Off
ADR") 

| 
---|--- 

11.3.

|

Promptly following timely receipt of the Set Off Dispute Notice, the Buyer
shall deposit the applicable Contingent Consideration into escrow with
SunTrust Bank or another escrow agent mutually acceptable to the Buyer and the
Sellers' Representative. The applicable Contingent Consideration shall be
released from escrow and paid in accordance with the decision of the
arbitrators in such Set Off ADR. 

| 
---|--- 

11.4.

|

For the avoidance of doubt, the set-off right set out in this paragraph 11
shall not apply to [***]. 

| 
---|--- 

12.

|

[***] 

[***].

| 
---|--- 

13.

|

CONDUCT OF THIRD PARTY CLAIMS 

| 
---|--- 

13.1.

|

The provisions of this paragraph 13 shall apply in the event that any third
party brings or makes (or threatens to bring or make) any claim, demand,
action or proceedings against any of the Buyer or a Buyer's Group Undertaking
which may reasonably be considered likely to give rise to a Claim (a "Third
Party Claim"). 

| 
---|--- 

13.2.

|

In the event of a Third Party Claim, the Buyer shall: 

 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.




 

--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

(a)

|

as soon as reasonably practicable [***] give written notice of the Third Party
Claim to the Sellers' Representative, specifying in reasonable detail the
nature of the Third Party Claim; 

| 
---|--- 

(b)

|

permit the Sellers' Representative to participate in the defence of (but not
conduct or control) such Third Party Claim at the expense of the Sellers'
Representative; 

| 
---|--- 

(c)

|

keep the Sellers reasonably informed (through the Sellers' Representative) of
the progress of, and all material developments in relation to, the Third Party
Claim; 

| 
---|--- 

(d)

|

provide the Sellers' Representative with copies of all material information
and correspondence relating to the Third Party Claim; and 

| 
---|--- 

(e)

|

give (and cause each relevant Buyer's Group Undertaking to give) the Sellers'
Representative and/or its professional advisers access at reasonable times
(and on reasonable prior notice) to its premises and personnel, and to any
relevant assets, accounts, documents or records within its control, for the
purposes of enabling the Sellers to assess the Third Party Claim and to
exercise their rights under this paragraph 13.2. 

| 
---|--- 

13.3.

|

The Buyer shall have the right in its sole discretion to conduct the defence
of and to settle or resolve such Third-Party Claim. However, without the prior
written consent of the Sellers' Representative, which consent will not be
unreasonably withheld, delayed or conditioned [***]. In the event that the
Sellers' Representative has consented in writing [***], neither the Sellers'
Representative nor any Seller shall have any power or authority to object
[***]. 

| 
---|--- 

13.4.

|

The Sellers shall indemnify the Buyer in respect of all costs, charges and
expenses that are reasonably and properly incurred by the Buyer (or any other
member of the Buyer's Group) in connection with the defence of a Third Party
Claim. 

| 
---|--- 

14.

|

PROVISION OF INFORMATION 

If, at any time after the date of this Agreement, a Seller wants to insure
against its liabilities in respect of a Claim, the Buyer shall provide such
information and assistance as a prospective insurer may reasonably require
before effecting the insurance.

| 
---|--- 

15.

|

PRESERVATION OF INFORMATION 

The Buyer shall, and shall ensure that each Buyer Group Company will, use
reasonable endeavours to preserve all documents, records, correspondence,
accounts and other information whatsoever relevant to a matter which may give
rise to a Claim.

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.


 

--- 
| | 

CONFIDENTIAL

|


| 
---|--- 

16.

|

RELEASING SELLER FROM LIABILITY 

The Buyer may release or compromise in whole or in part the liability of any
of the Sellers under this Agreement or grant any time or indulgence to that
Seller without affecting the liability of any other Seller.

| 
---|--- 

17.

|

CONTINGENT LIABILITIES 

If any potential Claim arises as a result of a contingent or unquantifiable
liability of any Buyer's Group Undertaking, each Seller will not be obliged to
pay any sum in respect of the potential Claim until the liability either
ceases to be contingent or becomes quantifiable; provided, however, that this
paragraph 17 shall not restrict the Buyer from setting off and deducting the
Buyer's reasonable estimate of any such potential Claim from Contingent
Consideration, as permitted by paragraph 11.


 

--- 
| | 

CONFIDENTIAL

|



 

--- 
| | 

EXECUTED and DELIVERED as a DEED by DENALI THERAPEUTICS INC. acting by an
authorised officer

|

)

)

)

|





â¦/s/ Steve Krognesâ¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

In the presence of:

|

| 

|

| 

Signature of Witness:

|

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

|

| 

Name of Witness:

|

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

|

| 

Address of Witness:

|

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.


 

|

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

|

| 

Occupation of Witness:

|

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

|

| 

 


 

--- 
| | 

CONFIDENTIAL

|



 

--- 
| | 

EXECUTED and DELIVERED as a DEED by SHAREHOLDER REPRESENTATIVE SERVICES LLC.
acting by an authorised officer

|

)

)

)

|





â¦/s/ [***]â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

In the presence of:

|

| 

Signature of Witness:

|

|



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

|

| 

Name of Witness:

|

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

|

| 

Address of Witness:

|

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.


 

|

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

|

| 

Occupation of Witness:

|

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

|

| 

 


 

--- 
| | 

CONFIDENTIAL

|

84

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 


 

--- 
| 

EXECUTED and DELIVERED as a DEED by [***]

an authorised signatory of

ATLAS VENTURE ASSOCIATES VII, INC. acting in its capacity as general partner
of ATLAS VENTURE ASSOCIATES VII, L.P. acting in its capacity as general
partner of ATLAS VENTURE FUND VII, L.P.



In the presence of:

|















â¦/s/ [***]â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

 



Signature of Witness:

|





â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

 

Name of Witness:

|



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

 

Address of Witness:

|



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

 

Occupation of Witness:

|



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.


 

 


 

--- 
| | 

CONFIDENTIAL

|

85

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 


 

--- 
| 

EXECUTED and DELIVERED as a DEED

by [***]

an authorised signatory of

AESCAP VENTURE MANAGEMENT B.V. acting as manager of

COÃPERATIVE AESCAP VENTURE I U.A.



In the presence of:

|







â¦/s/ [***]â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

 



Signature of Witness:

|





â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Name of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Address of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

Occupation of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.


 

 


 

--- 
| | 

CONFIDENTIAL

|

86

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 


 

--- 
| 

EXECUTED and DELIVERED as a DEED by TVM LIFE SCIENCE VENTURES VI GMBH and CO. KG
acting by ________________________, authorised signatory



In the Presence of:

|





â¦/s/ [***]â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

 



Signature of Witness:

|





â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Name of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Address of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

Occupation of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.


 

 


 

--- 
| | 

CONFIDENTIAL

|

87

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 


 

--- 
| 

EXECUTED and DELIVERED as a DEED by ______________________, authorised
signatory of TVM LIFE SCIENCE VENTURES VI CAYMAN LIMITED acting as a general
partner of

TVM LIFE SCIENCE VENTURES VI LIMITED PARTNERSHIP



In the Presence of:

|









â¦/s/ [***]â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

 



Signature of Witness:

|





â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Name of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Address of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

Occupation of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.


 

 


 

--- 
| | 

CONFIDENTIAL

|

88

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 


 

--- 
| 

EXECUTED and DELIVERED as a DEED by MP HEALTHCARE VENTURE MANAGEMENT, INC.
acting by _______________________, an authorised signatory

In the Presence of:

|





â¦/s/ [***]â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

 

Signature of Witness:

|



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Name of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Address of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Occupation of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.


 

 


 

--- 
| | 

CONFIDENTIAL

|

89

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 


 

--- 
| 

EXECUTED and DELIVERED as a DEED by MERCK VENTURES B.V. acting by
_______________________, an authorised signatory

In the Presence of:

|





â¦/s/ [***]â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

 

Signature of Witness:

|



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Name of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Address of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

Occupation of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.


 

 


 

--- 
| | 

CONFIDENTIAL

|

90

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 


 

--- 
| 

EXECUTED and DELIVERED as a DEED by S.R. ONE, LIMITED acting by [***], a duly
authorised officer

In the Presence of:

|



â¦/s/ [***]â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

 

Signature of Witness:

|



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Name of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Address of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

Occupation of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.


 

 


 

--- 
| | 

CONFIDENTIAL

|

91

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request. 


 

--- 
| 

 





EXECUTED and DELIVERED as a DEED by [***]

In the Presence of:

|









â¦/s/ [***]â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦ 

 

Signature of Witness:

|



â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Name of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Address of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦.

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

Occupation of Witness:

|

â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦â¦. 

 

 
--- 
| | 

CONFIDENTIAL

|

92

| 

*** Certain information in this agreement has been omitted and filed
separately with the Securities and Exchange Commission. [***] indicates that
text has been omitted and is the subject of a confidential treatment request.



\t    '

